University of Kentucky

UKnowledge
University of Kentucky Doctoral Dissertations

Graduate School

2008

THE EFFECT OF PPARγ
PPAR ACTIVATION BY PIOGLITAZONE ON THE
LIPOPOLYSACCHARIDE-INDUCED PGE2 AND NO PRODUCTION:
POTENTIALUNDERLYING ALTERATION OF SIGNALING
TRANSDUCTION
Bin Xing
University of Kentucky, bxing3@email.uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Xing, Bin, "THE EFFECT OF PPARγ ACTIVATION BY PIOGLITAZONE ON THE LIPOPOLYSACCHARIDEINDUCED PGE2 AND NO PRODUCTION: POTENTIALUNDERLYING ALTERATION OF SIGNALING
TRANSDUCTION" (2008). University of Kentucky Doctoral Dissertations. 629.
https://uknowledge.uky.edu/gradschool_diss/629

This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been
accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

ABSTRACT OF DISSERTATION

Bin Xing

The Graduate School
University of Kentucky
2008

THE EFFECT OF PPARγ ACTIVATION BY PIOGLITAZONE ON THE
LIPOPOLYSACCHARIDE-INDUCED PGE2 AND NO PRODUCTION: POTENTIAL
UNDERLYING ALTERATION OF SIGNALING TRANSDUCTION

ABSTRACT OF DISSERTATION
A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Medicine
at the University of Kentucky
By
Bin Xing
Lexington, Kentucky
Director: Dr. Guoying Bing
Associate Professor of University of Kentucky
Lexington, Kentucky
2008
Copyright © Bin Xing 2008

ABSTRACT OF DISSERTATION

THE EFFECT OF PPARγ ACTIVATION BY PIOGLITAZONE ON THE
LIPOPOLYSACCHARIDE-INDUCED PGE2 AND NITRIC OXIDE PRODUCTION:
POTENTIAL UNDERLYING ALTERATION OF SIGNALING TRANSDUCTION
Microglia-mediated neuroinflammation plays an important role in the
pathogenesis of Parkinson's disease (PD). Uncontrolled microglia activation produces
major proinflammatory factors including cyclooxygenase 2 (COX-2) and inducible nitric
oxide synthase (iNOS) that may cause dopaminergic neurodegeneration. Peroxisome
proliferator-activated receptor γ (PPARγ) agonist pioglitazone has potent antiinflammatory property. We hypothesize pioglitazone protects dopaminergic neuron from
lipopolysaccharide (LPS)-induced neurotoxicity by interacting with relevant signal
pathways, inhibiting microglial activation and decreasing inflammatory mediators.
First, the neuroprotection of pioglitazone was explored. Second, the signaling
transductions such as jun N-terminal kinase (JNK) and the interference with these
pathways by pioglitazone were investigated. Third, the effect of pioglitazone on these
pathways-mediated PGE2 / nitric oxide (NO) generation was investigated. Finally, the
effect of PPARγ antagonist on the inhibition of PGE2 / NO by pioglitazone was explored.
The results show that LPS neurotoxicity is microglia-dependent, and pioglitazone
protects neurons against LPS insult possibly by suppressing LPS-induced microglia
activation and proliferation. Second, pioglitazone protects neurons from COX-2 / PGE2
mediated neuronal loss by interfering with the NF-κB and JNK, in PPARγ-independent
mechanisms. Third, pioglitazone significantly inhibits LPS-induced iNOS / NO
production, and inhibition of LPS-induced iNOS protects neuron. Fourth, inhibition p38
MAPK reduces LPS-induced NO generation but no effect is found upon JNK inhibition,
and pioglitazone inhibits p38 MAPK phosphorylation induced by LPS. In addition,
pioglitazone increases PPARγ phosphorylation, followed by the increased PI3K/Akt
phosphorylation. Nevertheless, inhibition of PI3K increases LPS-induced p38 MAPK
phosphorylation. Inhibition of PI3K eliminates the inhibitive effect of pioglitazone on
the LPS-induced NO production, suggesting that the inhibitive effect of pioglitazone on
the LPS-induced iNOS and NO might be PI3K-dependent.

In summary, the results suggested that pioglitazone protects neurons by inhibiting
microglia-mediated COX-2 and iNOS, by differentially interacting with LPS-induced
JNK, NF-kB, and p38 MAPK signaling. Particularly, pioglitazone reduces JNKmediated COX-2 / PGE2 and p38 MAPK-mediated iNOS / NO. It is worth noting that
the inhibitive effect of pioglitazone on LPS-induced NO might be dependent on the PI3K
activation. In addition, our results suggest that both PPARγ-dependent and PPARγindependent mechanisms might be involved in the inhibitive effect of pioglitazone on
LPS-induced PGE2 and NO generation.

KEYWORDS: microglia, dopaminergic neurons, cytokines, signaling pathways,
pioglitazone
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CHAPTER 1: Introduction

Idiopathic Parkinson’s disease (IPD) is a common neurological progressive movement
disorder with an incidence of 1-3% among the population (Bennett et al., 1996; Lang and
Lozano, 1998). The primary pathology is the significant loss of pigmented dopaminergic
neurons in the substantia nigra (SN) and accordingly gradual depletion of striatal
dopamine, leading to its cardinal movement symptoms: resting tremor, rigidity, slowed
movement (named bradykinesia), and postural instability. As of now, pharmacological
treatment of PD such as levodopa and dopamine agonists can only suppress symptoms.
Long-term treatment will develop the medication-induced complications such as
dyskinesias characterized by involuntary and excessive movement.

So it is very

important to understand the molecular mechanisms underlying its pathogenesis. Several
neurotoxins, including 6-hydroxydopamine (6-OHDA) (Ungerstedt, 1968), 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston et al., 1984), LPS (Castano et al.,
1998), and rotenone (Betarbet et al., 2000) have been used to study its pathological
process.
Although its etiology is still not completely known, chronic neuroinflammation,
oxidative stress, apoptosis, stress, mitochondrial and proteasomal dysfunction are
implicated in its pathogenesis (McGeer et al., 1988b; McGeer et al., 1988a; Hirsch et al.,
1997; Jenner, 1998; Greenamyre et al., 1999; Olanow and Tatton, 1999). Indeed, upregulated inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) are
observed in the postmortem PD brain samples (Knott et al., 2000; Teismann et al., 2003b;
Teismann et al., 2003a), and are associated with the death of dopaminergic neurons in
vitro (Okuno et al., 2005; Lin et al., 2007) and in vivo (Liberatore et al., 1999; Teismann
and Ferger, 2001; Arimoto and Bing, 2003; Vijitruth et al., 2006).
Peroxisome proliferator-activated receptor γ (PPARγ) activation has been known
to negatively mediate microglial and macrophage activation (Jiang et al., 1998; Ricote et
al., 1998; Bernardo and Minghetti, 2006; Drew et al., 2006), which may play a central
role in the dopaminergic neuronal death.

Recently, there have been a few studies

demonstrating that activation of PPARγ with its agonists protects dopaminergic neurons
against MPTP and LPS insult (Breidert et al., 2002; Dehmer et al., 2004; Hunter et al.,
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2007), however, the underlying mechanisms of neuroprotection with PPARγ agonists is
not completely known. This part of the dissertation will seek to examine the effect of
PPARγ activation with its synthetic ligand pioglitazone on the LPS-induced up-regulation
of COX-2 and iNOS, to explore the potentially differential role of its activation in
dopaminergic neurons and microglial cells, and to investigate the role of signaling
transduction pathways (p38 MAPK, JNK, and PI3K/Akt) involved in the LPS-induced
PGE2 / nitric oxide and their interference with PPARγ agonist. The first specific aim was
to investigate whether LPS-induced dopaminergic neuronal loss is microglia-dependent
or not by utilizing various primary rat cell culture systems. The second aim focused on
the role of PPARγ activation in the signaling pathways associated with the LPS-induced
PGE2 and NO production. This chapter summarizes the relevant studies on the LPS and
PPARγ,

its

interference

with

cytotoxic

molecules

including

cytokines

and

proinflammatory factors, and its potential to be used in the neurodegenerative diseases.
Introduction to LPS studies relevant to Parkinson’s disease
LPS is a strong inducer of neuroinflammation and oxidative stress. It showed that
intranigral LPS injection in rats (2μg, from E. coli) induces a decrease in tyrosine
hydroxylase (TH) positive immunoreactivity with a decrease in the dopamine level on the
sites of both SN and striatum, which are accompanied with microglia activation (Castano
et al., 1998). A further study from same group demonstrated that the neurotoxicity of
intranigral LPS injection is specific to dopaminergic neurons, compared with
serotoninergic and GABAergic neurons (Herrera et al., 2000).

All above studies

implicated an important role of microglia activation in the dopaminergic neuronal death.
An LPS in vitro rat model showed that LPS (4μg/ml) did not induce dopaminergic
neuronal loss in a primary mesencephalic culture. The presence of added microglia,
however, was associated with the significant loss of dopaminergic neurons. In addition,
their study suggested that nitric oxide may mediate microglia-induced dopaminergic
neuronal death

(Le et al., 2001), consistent with the results from intranigral LPS

injection study in which the role of microglial iNOS was implicated (Arimoto and Bing,
2003). On the other hand, an LPS infusion PD model provided evidence that activated
microglia-induced superoxide may play a critical role in dopaminergic degeneration (Gao
et al., 2002). A few in vitro studies linked the activated MAPKs cascades with the death
2

of dopaminergic neurons (Lund et al., 2005; McLaughlin et al., 2006). In their study,
pretreatment of CEP1347, an inhibitor for mitogen-activated protein kinase kinase kinase
(MAPKKK), suppressed LPS-induced phosphorylation of p38 MAPK and JNK which
are downstream to MAPKKK, suggesting the involvement of MAPKs during the
inflammatory response in the microglia. Very recently, results from an LPS intranigral
model showed that co-injection of LPS with p38 MAPK inhibitor rescued dopaminergic
neurons in the SN, accompanied with reduced iNOS expression (Ruano et al., 2006).
Two years ago, people observed that rat intranigral LPS injection induces COX-2
expression and PGE2 synthesis in the SN (de Meira Santos Lima et al., 2006), consistent
with previous results from other studies of PD animal models (Feng et al., 2002;
Teismann et al., 2003b; Sanchez-Pernaute et al., 2004; Vijitruth et al., 2006). Almost at
the same time, a coculture study on mice primary microglia and rat primary neurons upon
LPS insult suggested that the LPS-induced PGE2 level is increased in a microglia densitydependent manner (McLaughlin et al., 2006). The above studies strongly suggested that
uncontrolled activated microglia-mediated inflammation can be detrimental to
dopaminergic neurons, probably via the activation of MAPKs pathways and increasing
iNOS / COX-2 expression.

However, the direct relationship between activated

microglia-mediated neuroinflammation and the dopaminergic neuronal degeneration is
still not completely investigated. Both LPS in vivo and in vitro studies can not rule out
the neuroprotective and / or neurotoxic role of astrocytic cells under certain conditions
since either primary mesencephalic cultures or primary mesencephalic-glia cultures were
used in their studies. In addition, the biochemical responses of neuronal and microglia
cell lines to neurotoxin LPS can not be easily compared with the responses from the
primary cells. The following Table 1.1 summarizes LPS in vitro and in vivo studies
relevant to Parkinson’s disease.

3

Table 1. 1 Summary of LPS in vivo and in vitro studies relevant to Parkinson's disease.
(page 4-5)
Model

Doses

Relevant findings

Reference

Intranigral injection

2μg

Decreased TH+ cells

(Castano et al., 1998)

Wistar rats

Decreased DA level
Microglia activation

Intranigral injection

2μg

LPS neurotoxicity is specific to DA neurons

Wistar rats

(Herrera et al., 2000)

Microglia activation

Coculture of

4 μg/ml

TH+ cell loss when microglia added.

(Le et al., 2001)

5μg

iNOS protein increased in SN.

(Arimoto and Bing,

iNOS inhibitor L-NNA injection in SN

2003)

primary
mesencephalic and
primary microglia
(rats)
Intranigral injection
SD rats

rescued neurons
Infusion LPS Fisher

5ng/hr

rats

weeks

x

2

Microglia activation preceded selective

(Gao et al., 2002)

neuronal loss.
Superoxide might be important

LPS in vitro E15 rat

10-80μg/ml

Selective neuronal loss

(Gayle et al., 2002)

iNOS inhibitor L-NIL did not rescue neurons.
1mg/kg

Single

Decreased DA neurons

(Ling et al., 2002)

Decreased DA level

Intraperitoneal
injection SD female
rats

E10.5,

pups

killed at p21
Intranigral injection
into

5μg

NADPH

NADPH oxidase-generated ROS mediates

(Qin et al., 2004)

neurotoxicity

deficient mice
Microglia cell line

100ng/ml

MAPKs pathway might be involved

(Lund et al., 2005)

1-100ng/ml

Caspase-3

(Wang et al., 2005)

(BV-2)
Primary
mesencephalic
culture;

activation

neuronal loss

microglia

culture, PC12 cell
culture

4

in

dopaminergic

Mouse macrophage
cell

line

10ng/ml

NO-dependent neurotoxicity

(Shavali et al., 2006)

1 μg

Inhibition of p38 MAPK decreased LPS-

(Ruano et al., 2006)

RAW

264.7,
dopaminergic

cell

line SH-SY5Y
Intranigral injection

induced iNOS

Intraperitoneal

5mg/kg

Microglia activation and deceased TH+ cells.

(Qin et al., 2007)

injection TNFR1/R2
TNFR1/R2-/- resistant to the increase of TNFα

deficient mice

in brain

Intrastriatal injection

16-60 μg LPS

Pioglitazone rescued TH+ neurons with

SD rats

20mg/kg;

inhibition of iNOS and COX-2.

orally

Pioglitazone suppressed protein oxidation

(Hunter et al., 2007)

administrated
pioglitazone

Table 1.1 continued

* DA = dopamine; L-NNA= NG-nitro-L-Arginine; L-NG-Nitroarginine, NOS inhibitor; i.c.v =
intracerebroventricular; TNFR1/R2 = Tumor necrosis factor α receptor 1 / 2; L-NIL = dihydrochloride,
relative selective inhibitor of iNOS

General introduction to PPARs
PPARs are ligand-inducible transcription factors belonging to the superfamily of nuclear
receptors.

There are three isotypes identified as of now.

They are structurally

homologous: PPARα (NR1C1) (Issemann and Green, 1990), PPARβ (NR1C2), and
PPARγ (NR1C3) (Michalik and Wahli, 1999; Torra et al., 2001). PPARs play a central
role in the regulation of lipid metabolism and glucose homeostasis, well-known effects
that have been used to develop drugs for treatment of type II diabetes (Auwerx, 1999).
Their differential physiological functions are related to their distinct expression
and localization in a variety of cell types and tissues.

Although they are mainly

expressed in the tissues with high fatty acid metabolism including liver and adipose tissue,
the expression of all three isotypes are observed in neurons. Recently, there has been
much interest in the potent inhibitive effects of PPARs on inflammation and oxidative

5

stress, suggesting their role in treating neurodegenerative diseases (Heneka et al., 1999;
Combs et al., 2000; Heneka et al., 2000; Sastre et al., 2003; Bernardo et al., 2005; Heneka
et al., 2005).
Distribution of PPARγ and other isotypes
Developmentally, PPARγ transcription was observed on gestation of day 13.5 in the CNS
and on 18.5 in the brown adipose tissue in rat and mouse (Heneka and Landreth, 2007).
High levels of PPARα expression are found in the liver, kidney, intestine, skeletal muscle,
and the pancreas. In contrast, PPARβ is expressed ubiquitously and earlier during fetal
development (more detail in Heneka review (Heneka and Landreth, 2007) ). In adult
rodent including rat and mice, the distribution of PPARγ and PPARα is similar to their
expression observed in the fetal period, and PPARβ transcript is more abundant than the
PPARα and γ transcripts.
However, the expression of PPARs is less understood during human development.
A few studies have showed that human PPARγ is also abundantly expressed in adipose
tissue, with lower levels in skeletal muscle, the heart, and the liver. Noticeably, it is
present in the macrophages (Huang et al., 1999; Barish et al., 2005). PPARα is most
highly expressed in tissues with fatty acid catabolism like PPARγ.

Similar to the

expression pattern observed in the rodent, PPARβ expression is ubiquitous.
Importantly, expression of all three PPARs is observed in the CNS during late rat
embryogenesis and in the adult, of which the PPARγ is found dominantly in microglia.
In astrocytes all three PPAR isotypes are found with different degrees. The following
table 1.2 summarizes PPAR distribution in the peripheral tissues and in the CNS.
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Table 1. 2 Distribution and functions of PPARs in mammal tissues.
Isotype

Brown

White

adipose

adipose

Kidney

Intestine

Heart

Muscle

Liver

Pancreas

Rat CNS
(all

tissue

tissue

isotypes

Functions

express in
brain
except
following
areas or
cells)
PPARα

+++

+

++

++

++

++

+++

++

Hypothala

Lipid

mus (-)

Catabolism;

VTA (-)

Anti-

Purkinje

inflammation

cell (-)
Granule
cell (-)
Oligodend
rocyte (-)
PPARβ

++

++

++

++

++

+++

++

No study

Lipid
homeostasis;
Oligodendro
cyte
differentiatio
n?
Antiinflammation

PPARγ

++

+++

++

++

++

++

++

No study

VTA (-)

Lipogenesis;

Purkinje

Anti-

cell (-)

inflammation

Telenceph
alon (-)
Oligodend
rocyte (-)

VTA = ventral tegmental area; (-) means not found. Empty cell means no study was
found.
Based on: (Moreno et al., 2004)
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PPAR structure and putative mechanisms of their function
Although PPAR isotypes are encoded by distinct genes on different chromosomes, they
are homologous in structure. Generally, there are four major domains in the PPAR
structure. Their N-terminal A/B domain takes part in the ligand-independent regulation
of receptor activity, the DNA-binding domain (DBD) is highly conserved among the
three isoforms and is linked to the C-terminal ligand-binding domain (LBD). Its E/F
domain is responsible for the ligand-dependent transactivation function, and its D domain
is characteristic of a variable hinge region (Kersten, 2000, 89:141). (Figure 1.1)

Figure 1. 1 PPARs structure
Four main distinct regions are contained in PPARs, from A/B to E/F domain. The Nterminal A/B domain contains ligand-independent activity, C domain contains a DNAbinding domain, D is characteristic of a variable hinge region, and E/F is ligand-binding
domain with a ligand-dependent activity. Shown here is its heterodimer retinoic acid
receptor (RXRα) binding to the peroxisome proliferator response element on the target
genes. Modified from (Boitier et al., 2003).
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Although the exact mechanisms of how PPARs regulate gene expression remains
elusive, an increasing body of evidence suggested that multiple mechanisms might be
involved in these processes.
The first putative mechanism of its transcriptional control of gene expression is
named ligand-dependent transactivation via heterodimerizing with retinoid-S-receptors
(RXRs).

As shown in Figure 1.2 (1), coactivators such as CREB-binding protein

(CBP)/p300 are recruited, and the PPAR-RXR heterodimers binding to the typical PPAR
response elements (PPREs) on the promoter of target genes then activate related
transcription (Desvergne and Wahli, 1999; McKenna and O'Malley, 2002).
Noticeably, PPARs can inhibit proinflammatory gene expression by a second
putative mechanism named ligand-dependent transrepression via antagonizing the
activities of other transcription factors, including NF-kB and activator protein-1 (AP-1)
(Marx et al., 1998; Staels et al., 1998), without involving in PPREs binding, as shown in
Figure 1.2 (2). In this way, their target genes transcription can be transrepressed. A line
of evidence suggested that anti-inflammation of PPARγ agonists is related to this
mechanism (Pascual et al., 2005; Glass and Ogawa, 2006).
The third putative mechanism is named ligand-independent repression via
interaction of recruited corepressor complexes and PPARs, thus inactivating target genes,
as shown in Figure 1.2 (3). Dr. Dowell reported that PPARα can interact with nuclear
receptor corepressor directly in human embryonic 293 cells (Dowell et al., 1999).
However, whether other PPAR isotypes can function in this way remains to be studied.
For more detail see (Ricote and Glass, 2007).
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Figure 1. 2 Schematic graph shows gene expression by PPARs.
(1) Ligand-dependent transactivation. Ligand-binding recruits coactivator complexes,
bind to PPRE, and activates gene expression. (2) Ligand-dependent transrepression.
Ligand-binding with PPAR antagonizes activity of other transcription factor, shown here
is NF-kB inhibition. (3) Ligand-independent repression. Binding of PPAR to RXR
recruits corepressor complexes, which suppress gene expression. Modified from (Ricote
and Glass, 2007).
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PPARs and neurodegenerative diseases
Although neurodegenerative diseases are characterized by their distinct pathological
localization involved in the different groups of cells, excessive reactive microglia are
frequently observed in patients with Alzheimer’s disease (AD) (Rogers et al., 1988), PD
(McGeer et al., 1988b), multiple sclerosis (MS)(Gobin et al., 2001), and amyotrophic
lateral sclerosis (ALS) (Kawamata et al., 1992). An increasing body of evidence from
postmortem

studies

implicates

the

role

of

microglia

activation-mediated

neuroinflammation in the pathogenesis of neurodegenerative diseases. For example,
elevated levels of proinflammatory factors such as TNF-α and cytokines PGE2 in PD
(Mogi et al., 1994b; Mogi et al., 1994a; Mogi et al., 1996; Mogi et al., 2007) and AD
(Griffin et al., 1995) were found near the degenerating neurons. Animal in vivo and in
vitro studies of various neurodegenerative diseases showed that inhibition of these
cytotoxic molecules provides neuroprotection (Misko et al., 1995; Leonard et al., 1997;
Drachman and Rothstein, 2000; Zhu et al., 2002; Pompl et al., 2003; Nathan et al., 2005;
Ni et al., 2007; Kotilinek et al., 2008).
The anti-inflammation activities of PPARs were first noticed when a prolonged
inflammatory response was observed in PPARα null mice (Devchand et al., 1996). As of
now, it has been shown that all three PPAR isoforms can participate in the mediation of
inflammatory response. PPARβ deficient mice showed delayed would healing and its
agonist inhibited cytokine-induced vascular cell adhesion molecule in epithelial cells
(Michalik et al., 2001; Rival et al., 2002). PPARγ agonist 15-deoxy-D-prostaglandin J2
(15d-PGJ2) suppresses interferon-γ-induced iNOS protein and its mRNA in mouse
peritoneal macrophages (Ricote et al., 1998). Further study demonstrated that its agonists
can also inhibit proinflammatory factors such as TNF-α and interleukin-6 in different cell
types (Delerive et al., 2001).
Recent evidence indicates that PPAR agonists provide neuroprotection by
mediating inflammatory processes in animal models of PD (Dehmer et al., 2004), AD
(Combs et al., 2000; Landreth and Heneka, 2001), MS (Feinstein et al., 2002), and ALS
(Kiaei et al., 2005).
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PPARγ and Parkinson’s disease
Although the etiology of Parkinson’s disease is still not known, it is generally accepted
that unlimited activated microglia mediates dopaminergic neuronal loss via releasing
cytotoxic molecules including cytokines and proinflammatory factors. It was shown that
PPARγ activation with 15d-PGJ2 inhibits the level of TNF-α and iNOS protein / mRNA
expression in mouse peritoneal macrophage (Jiang et al., 1998; Ricote et al., 1998),
suggesting the effects of PPARγ activation on preventing inflammatory responses in the
brain. Indeed, one PPARγ synthetic agonist, troglitazone, suppresses cerebellar iNOS
expression and protected cerebellar granule cells against LPS/IFN-γ insult (Heneka et al.,
2000). A few studies from PD animal models have demonstrated that a PPARγ synthetic
agonist protects dopaminergic neurons accompanying with inhibited microglia activation
in a mice MPTP model (Breidert et al., 2002; Dehmer et al., 2004). Three days of orally
administrated pioglitazone prior to MPTP (i.p) treatment significantly protected
dopaminergic neurons from death, and iNOS-positive microglial cells were suppressed in
the pioglitazone-treated group (Breidert et al., 2002); further study from the same
research group suggested that pioglitazone protected TH positive neurons against MPTP
insult (30mg/kg i.p.) probably via PPARγ activation, NF-kB activation, and suppression
of iNOS expression (Dehmer et al., 2004).

Very recently, study on the molecular

mechanisms of our intrastriatal LPS-induced dopaminergic neuronal loss rat model
suggested that the dopaminergic neuronal protection by pioglitazone is associated with its
inhibition of microglia activation, iNOS and COX-2 expression, and restoration of
mitochondria function (Hunter et al., 2007). Table 1.3 summarizes current studies of
PPARγ agonists relevant to PD. However, 1) the potential inhibitory effect of the PPARγ
agonist pioglitazone on LPS-induced microglia activation, and 2) the role and signaling
transduction pathways of pioglitazone in activated microglia-mediated dopaminergic
neuronal death have not been investigated.

The hypothesis is 1) PPARγ agonist

pioglitazone inhibits LPS-induced microglia activation; and 2) pioglitazone protects
dopaminergic neuronal loss against neurotoxicity of microglia-mediated iNOS and COX2.
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Table 1. 3 Summary of current reference relevant to neuroprotection of PPARγ agonists.

Model

Major results

Reference

MPTP (i.p)

Protect DA neurons

(Breidert et al., 2002)

Inhibition of glial activation
MPTP (i.p)

Reduce iNOS positive cells

(Dehmer et al., 2004)

Induce IkBα expression
Inhibit NF-kB nuclear translocation
Intrastriatal LPS

Protect DA neurons

(Hunter et al., 2007)

injection

Inhibition of microglia activation
Inhibition of iNOS / COX-2

LPS in vitro

Protection of DA neurons via inhibiting microglia

(Xing et al., 2007)

activation
Inhibition of COX-2 via interference with JNK
and NF-kB
LPS in vitro

Suppresses p38 MAPK activation-mediated iNOS

(Xing et al., 2008)

possibly via activation of PPARγ and PI3K / Akt
pathway
MPTP (i.p)

Protection of DA neurons

(Quinn et al., 2008)

Inhibition of MPTP conversion to MPP+ via
suppressing MAO-B
*ip= Intraperitoneal injection; DA= dopaminergic neurons

MAPKs and PI3K in Parkinson’s disease
From extracellular stimuli such as proinflammatory cytokines to the target gene
expression, intracellular signaling transduction is tightly regulated in the divergent and
convergent manner. One of the best known proinflammatory pathways is mitogenactivated protein kinases pathways (MAPKs), which include p38 MAPK, JNK, and
ERK1/2. Dependent on different extracellular stimuli and different cell types, differential
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biological responses are tightly controlled following complicated sequential activation
from MAPKKKs to MAPKs. (Figure 1.3)

Figure 1. 3 Schematic graph of MAPK pathways.
A variety of extracellular signals such as growth factors and cytokines differentially
activate MAPKKKs such as Raf, MEKK, MLK, followed by sequential activation of
MAPKKs such as MEK1/2, and activation of MAPKs (ERK1/2, JNK, and p38), inducing
different biological responses. Based on (Gallo and Johnson, 2002) and website:
http://www.bch.msu.edu/faculty/gallo.htm.
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It is generally accepted that p38 MAPK and JNK pathways are two main
signaling cascades that modulate inflammatory response and stress (Kyriakis and Avruch,
2001). One small postmortem study on PD brains demonstrated the immunoreactivity of
their phosphorylation (Ferrer et al., 2001), and a very recent analysis from the extracts of
leukocytes from PD patients provided more evidence that the JNK activity was reduced
(White et al., 2007), suggesting these pathways are involved in the pathogenesis of PD.
On the other hand, experimental animal in vivo and in vitro studies strongly
implicated MAPK activation-mediated dopaminergic neuronal death in a MPTP / MPP+
model (Du et al., 2001; Gomez-Santos et al., 2002), 6-OHDA (Choi et al., 2004; GomezLazaro et al., 2008), rotenone (Zhao et al., 2006) and other models (Gomez-Santos et al.,
2003; Wilms et al., 2003; Choi et al., 2004; de Bernardo et al., 2004; Lee et al., 2005).
Although the involvement of p38 MAPK cascade with LPS-induced neuronal death in the
hippocampus was reported (de Bock et al., 1998), the MAPKs signaling transduction
associated with LPS-induced dopaminergic neuronal loss is still poorly understood. The
result from an in vitro study suggested that LPS-induced neuronal loss is prevented by the
inhibition of p38 MAPK pathway, accompanied by the decrease of NO production in the
primary mesencephalic culture (Jeohn et al., 2002). The other in vivo experimental study
demonstrated that inhibition of p38 MAPK not only rescues dopaminergic neurons but
also decreases iNOS expression (Ruano et al., 2006). The role of the JNK pathway in the
LPS model is less studied. The result from a midbrain slice culture study suggested that
inhibition of JNK activity rescues LPS/IFNγ-induced dopaminergic neuronal loss without
influencing iNOS expression (Shibata et al., 2006), suggesting that the activation of LPSinduced p38 MAPK and JNK pathways potentially mediates differential production of
cytotoxic molecules which ultimately lead to neuronal death. Recently, one clinical trial
(2007) on 806 patients with early PD using CEP1347, an inhibitor of JNK signaling
cascade, was done by the Parkinson Study Group. Although the results did not show
beneficial slowing down of the progression of PD, it suggests that the therapeutic
strategies should take multiple signaling cascades associated with inflammatory response
into account. The hypothesis is that LPS-induced activation of MAPK pathways
differentially mediate the iNOS/NO and COX-2 / PGE2 expression.
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PI3K phosphatidylinositol-3-OH kinase (PI3K) / Akt (also known as protein
kinase B, PKB) is a well-known cell survival signaling pathway. Neurotrophic factors
such as nerve growth factor, brain-derived neurotrophic factor, and insulin-like growth
factor I activate the PI3K/Akt cascade and promote neuronal survival and / or axonal
growth (Halvorsen et al., 2002; Nusser et al., 2002; Bonnet et al., 2004; Zhou et al., 2004;
Yoshii and Constantine-Paton, 2007). Neurotoxin studies in animals provided a link of
PI3K activity with neuronal survival (King et al., 2001; Halvorsen et al., 2002). Their
results demonstrated that inhibition of PI3K by LY294002 promotes MPP+-induced SHSY5Y apoptosis, and activation of Akt can protect cells (King et al., 2001), and nerve
growth factor treatment prevents SH-SY5Y apoptosis possibly via increasing the
phosphorylation of PI3K / Akt (Halvorsen et al., 2002).

However, the potentially

differential regulation of MAPK and PI3K pathways by PPARγ activation and their
differential roles in the LPS-induced iNOS and COX-2 expression is not completely
understood.

The hypothesis is that the PPARγ agonist pioglitazone protects

dopaminergic neurons by the inhibition of iNOS and COX-2 expression via potentially
differential mediation of MAPK and PI3K activity.
Overview of experimental aims
Although intensive studies have been done to investigate the molecular mechanisms of
the pathogenesis in PD, and several common mechanisms such as neuroinflammation and
oxidative stress are generally accepted, the role of neuroinflammation-mediated signaling
transduction in dopaminergic neuronal loss and their interference with PPARγ agonist is
poorly understood. The experimental studies described in this dissertation primarily
address the following general hypotheses: 1) LPS-induced dopaminergic neuronal death
is microglia-dependent. It is easy to manipulate different primary cell cultures and
differentiate the role of microglial activation in the degeneration of dopaminergic neurons.
2) a PPARγ agonist protects against LPS-induced neurotoxicity via inhibiting p38 MAPK
/ JNK pathways, which potentially have differential roles in mediating iNOS and COX-2
expression. 3) a PPARγ agonist might also protect dopaminergic neurons via activating
the PI3K/Akt pathway, which probably mediates p38 MAPK / JNK activity.
detailed hypotheses and specific aims will be presented in each chapter.
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The

The general profile of PPARγ activation by its synthetic ligand pioglitazone and
the influence of LPS on its activation were evaluated by western blot. To measure the
effect of PPARγ activation by pioglitazone on LPS-induced microglial activation and
dopaminergic neuronal loss, primary microglia-enriched cultures, primary neuronmicroglia mixed culture and primary neuron-enriched cultures were used, and
immunocytochemistry for microglia and TH positive neurons was done. The effect of
PPARγ activation on the activity of MAPKs (p38 MAPK and JNK) and the PI3K/Akt
pathway was evaluated by western blot, and the selective inhibitors of p38 MAPK
(SB203580) and JNK (SP600125) were used to access the effect of their inhibition on
LPS-induced PGE2 and nitric oxide production in primary microglia-enriched cultures.
The role of PI3/Akt activation in the mediation of p38 MAPK / JNK activity was
evaluated by its selective inhibitor wortmannin in primary microglia-enriched cultures.
The effect of PPARγ activation on the activity of the COX-2 and iNOS, which are the
rate-limiting enzymes for PGE2 and NO, respectively, was measured by western blot.
The inhibition of COX-2 and iNOS on LPS-induced dopaminergic neuronal loss was
evaluated by immunocytochemistry.

Copyright © Bin Xing 2008
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CHAPTER 2: Dopaminergic neuronal loss induced by LPS is microglia-dependent
and PPARγ activation by pioglitazone is neuroprotective by inhibiting LPS-induced
microglial activation
(From published paper: B Xing., M Liu., GY Bing. (2007) J. Neuroimmunol. 192:89-98). M Liu took part
in the experiment in the immunocytochemistry.

Introduction
It has been demonstrated that glial-related cytokines are increased either in PD
postmortem study or in the assay of patients’ serum / cerebrospinal fluid (CSF). The
level of TNF-α from PD striatum and CSF is significantly higher than that in the control
group (Mogi et al., 1994a), and other cytokines including IL-6 and IL-1β are also
increased in the dopaminergic regions (Mogi et al., 1994b).
Although both activated glial cells (microglia / astrocytes) can release
proinflammatory cytokines under certain cellular stress, and may take part in the
detrimental process resulting to the death of dopaminergic neurons, increasing evidence
indicates that activated microglia rather than astrocytes play a major role in the
pathological process of PD. First, a large number of reactive microglia was found
surrounding dopaminergic neurons in the SN of PD brains (McGeer et al., 1988b).
Second, the SN area where dopaminergic neurons are degenerated has the highest density
of microglia in the brain, whereas astrocytes have a higher density in the hippocampus
and hypothalamus (Lawson et al., 1990; Savchenko et al., 2000). Third, a postmortem
SN study found that glial fibrillary acidic protein (GFAP) immunoreactivity for
astrocytes is often unobservable compared to the strong microglial immunostaining
(Banati et al., 1998). Fourth, animal experimental studies demonstrated that neurotoxininduced dopaminergic neuronal death is often preceded by microglia activation (Gao et
al., 2002).
As a potent inducer of inflammation, the LPS PD model provides a very useful
tool to study the mechanisms of microglia-mediated neuroinflammation in the
pathological process of PD, since LPS selectively induces the death of dopaminergic
neurons (Herrera et al., 2000) and microglia activation (Castano et al., 1998). The LPS
in vitro model provides a useful chance to study the detrimental role of both astrocytes
and microglia. However, the current in vitro model did not mechanically remove the role
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of astrocytes since either primary mesencephalic cultures or primary mesencephalic-glia
cultures were used in their studies. In this way, it is relatively difficult to explain the data.
To investigate the activated microglia-mediated neuroinflammation and the dopaminergic
neuronal degeneration, our LPS in vitro model systems were set up. From the reports
that LPS neurotoxicity is glia-dependent (Bronstein et al., 1995), the first hypothesis is
that LPS neurotoxicity is microglia-dependent and pioglitazone protects dopaminergic
neurons by inhibiting microglia activation. The first specific aim is to administer LPS
into both primary neuron-enriched cultures and primary neuron-microglia mixed cultures,
then to test the survival of dopaminergic neurons, and to obtain the optimal (minimal)
LPS toxicity concentration for the future study.
Several studies have suggested that PPARγ agonists inhibit macrophage /
monocyte activation-derived cytokines such as TNF-α and NO (Jiang et al., 1998; Ricote
et al., 1998). MPTP animal studies showed neuroprotection of a PPARγ agonist toward
dopaminergic neurons (Breidert et al., 2002; Dehmer et al., 2004).

The second

hypothesis is that the PPARγ agonist pioglitazone protects dopaminergic neurons via
inhibiting microglia activation in LPS in vitro model. The second specific aim is to test 1)
if pioglitazone inhibits LPS-induced microglia activation, and 2) if pretreatment of
pioglitazone into primary neuron-microglia mixed cultures shows a neuroprotective
effect.
Materials and methods
Animals
Twenty one timed-pregnant Sprague Dawley rats obtained from Harlan (Indianapolis, IN,
USA) and were maintained in a strict pathogen free environment. Animal use was
performed in strict accordance with the National Institutes of Heath guidelines and was
approved by the Institute’s Animal Care and Use Committee at the University of
Kentucky.
Reagents
Salmonella minnesota LPS and pioglitazone were obtained from Sigma-Aldrich (St Louis,
MO, USA), Ara-C was obtained from Sigma-Aldrich (St Louis, MO, USA), antibodies
used were as follows: polyclonal anti-tyrosine hydroxylase (TH) antibody from Pel-Freez
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Biologicals (Rogers, AR, USA), monoclonal anti-rat CD11blc antibody for OX-42 from
Pharmingen (San Jose, CA, USA), and monoclonal anti-β-actin from Sigma-Aldrich (St.
Louis, MO, USA). The ABC kit and biotinylated secondary antibodies were purchased
from Vector Laboratories (Burlingame, CA, USA). All culture medium and products
were obtained from Invitrogen (Carlsbad, CA, USA).
Mesencephalic neuron-microglia mixed cultures
Neuron-glia cultures were prepared from the SD ventral mesencephalic tissues of
embryonic day 13-14. Briefly, midbrain tissues were dissected from day 14 SD rat
embryos in Ca++/Mg++ free medium (CMF).

Cells were dissociated via gentle

mechanical trituration in Hanks’ Balanced Salt Solution (HBSS) containing newborn calf
serum (3.5:1 v/v). The concentration of the cell suspension was ~ 1.2 x 107 cells / ml
before seeding, and the cells were seeded in poly D-lysine (50μg/mL) pre-coated 24-well
plates (1 x 105/well). Cells were fed with Dulbecco’s Modified Eagle Medium (DMEM /
F12) containing 10% horse serum and 10% fetal bovine serum. Three days after seeding,
the cells were replenished with 500ml of fresh DMEM / F12 with 5% horse serum and
fetal bovine serum. At DIV6 or DIV7, 2 x 105 microglia were added into primary
mesencephalic neuron-enriched cultures containing 1 x 105 cells/well, and after 24h, the
cultures were treated with either pioglitazone or LPS dissolved in DMSO, and the control
groups were only treated with same amount of DMSO (10μl).
Primary mesencephalic neuron-enriched cultures
Twenty four hours after seeding, 5μM Ara-C was added into the culture medium for 48h,
followed by replacement with fresh DMEM / F12 medium with 5% horse serum and fetal
bovine serum. Cultures were exposed to treatment seven days after seeding.
Microglia-enriched cultures
Primary glial cell cultures were established from cerebral cortices of 2-3 day-old neonatal
SD rats. Briefly, cerebral cortices were minced and gently dissociated by repeated
pipetting in HBSS supplemented with fetal bovine serum (3.5:1 v/v).

Cells were

collected by centrifugation at 1000g for 6mins, resuspended in DMEM containing 10%
fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin, and were cultured on
175cm2 cell culture flasks in 5% CO2 at 37°C.
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Floating microglia were harvested

between 2-8 weeks by shaking off at 200rpm, and the concentration of the cell
suspension was ~1.4 x 106 microglial cells/ml and were re-seeded back into 24-well
plates (2 x 105) for other assays. After 30mins, cultures were washed to remove nonadherent cells and fresh medium was added, and the cultures were treated 24h after
seeding.
Immunocytochemistry
Culture medium was removed and the cells were rinsed in Tris buffer (pH = 7.3), fixed in
4% paraformaldehyde for 20mins, and rinsed again in Tris. Non-specific staining was
blocked with 10% goat serum or horse serum for 60mins. Cells were incubated overnight
at 4°C with primary anti-TH antibody (1:10,000) or anti-OX-42 primary antibody
(1:1000). After several Tris rinses, cells were incubated with the following biotinconjugated secondary antibodies for 1hr: goat anti-rabbit IgG (1:1000) for TH or horse
anti-mouse IgG (1:1000) for OX-42. The cells were rinsed several times and incubated
in an ABC-peroxidase reagent for 1hr. This was followed by several rinses and a color
development with 3,3'-diaminobenzidine and 0.03% H2O2 in Tris buffer. Images were
acquired using a Zeiss Axioplan 2 microscope connected to a digital Zeiss Axio camera
operated with AxioVision software (Zeiss). To quantify OX-42 positive cells, nine
representative areas per well, in the 24-well plate, were counted under the microscope at
100X magnification, and the microglia with an expanding transparent part were
considered as activated. The TH-positive neurons were counted in each 24-well plate,
and the averages are reported. TH-immunostained neurons were considered healthy, if
the length of all the neurites was two times longer than the diameter of its cell body and if
the cell had at least two neurites.
Statistical Analysis
The data are expressed as the mean ± SEM and statistical significance was assessed by
ANOVA followed by a Tukey comparisons test using the SYSTAT 10 software (SPSS
Inc., Chicago, Illinois). A value of p < 0.05 was considered statistically significant.
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Results
LPS neurotoxicity is microglia-dependent and the PPARγ agonist pioglitazone protects
dopaminergic neurons against LPS insult
It has been shown that LPS neurotoxicity is glia-dependent in mesencephalic cultures
(Bronstein et al., 1995), but the effect of astrocytes were not excluded in their study. In
order to test if LPS toxicity in our culture system is microglia-dependent, and to facilitate
studying the cellular and molecular mechanisms between initial microglial activation and
secondary dopaminergic neuronal death, the survival of TH-positive neurons upon LPS
exposure, in the presence and absence of microglia, was investigated in primary neuronenriched and neuron-microglia mixed cultures. We found that LPS failed to induce
dopaminergic neuronal loss in neuron-enriched cultures (Figure 2.1). In contrast, in the
presence of microglia, 1-40μg/ml LPS induced ~38-75% loss of the dopaminergic
neurons (Figure 2.2) after a 72hr LPS treatment. Pretreatment with pioglitazone (10μM),
1hr prior to LPS (1μg/ml), significantly protected dopaminergic neurons by about 90%
compared to the 60% cell loss upon LPS (1μg/ml) alone (p<0.05, Figure 2.2).
Pioglitazone alone did not alter cell viability.
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Figure 2. 1 LPS treatment in primary neuron-enriched cultures.
Rat mesencephalic neuron-enriched cultures (1×105 cells/well) were treated with LPS for
72 h, and examined with immunocytochemistry for TH-positive neurons. A: Increasing
concentrations of LPS (a–h) did not decrease the number of TH-positive neurons. Both
control and LPS treated groups had long smooth neuritis. B: No significance difference
was found between control group and different doses of LPS groups (5ng/ml-40μg/ml).
The data were expressed as the percentage of control and were the mean ± SEM, from
three independent experiments. (n=3). (a=control; b=LPS 5 ng/ml; c=LPS 10 ng/ml;
d=LPS 50 ng/ml; e=LPS 100 ng/ml; f=LPS 1 μg/ml; g=LPS 10 μg/ml; h=LPS 40 μg/ml).
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Figure 2. 2 LPS is neurotoxicity in neuron-microglia mixed cultures.
Rat neuron-microglia cultures (with 1×105 neurons and 2×105 microglia per well) were
treated with various doses of LPS (5ng–40μg/ml) for 72 h, and the number of THpositive neurons was examined with immunocytochemistry. A: control cultures have
long and smooth neurites (a), LPS (1μg/ml) treated cultures have discontinuous neurites
(b), and LPS (1μg/ml – 40μg/ml) induces a dose-dependent neurotoxicity as indicated by
the discontinuous neurites (b). Pioglitazone (10μM) alone did not influence the general
morphology and survival of the TH positive neurons (c). Pretreatment with pioglitazone
(10μM) 1 h before LPS (1μg/ml) treatment represented in (d) showed normal
morphology. B: LPS did not show neurotoxicity from 0.005μg/ml to 0.5μg/ml, however,
1μg/ml-40μg/ml LPS showed dose-dependent neurotoxicity. C: LPS (1μg/ml) decreased
the number of TH positive neurons, and pretreatment of pioglitazone protected the THpositive neurons against cell death, as determined by cell counts.

The data were

expressed as the percentage of control and were the mean ± SEM, from three independent
experiments. (n=3) (**p<0.01 versus control, #p<0.05 versus LPS).

Pioglitazone suppresses LPS-induced microglia activation
LPS did not induce dopaminergic neuronal loss in the absence of microglia and
pioglitazone protected dopaminergic neurons against LPS neurotoxicity in the presence
of microglia, suggesting its neurotoxicity is dependent on microglia. In the next step we
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tested the effect of pioglitazone on microglia activation.

First, microglia-enriched

cultures were treated with LPS (100ng-1μg/ml) in the presence or absence of pioglitazone
(10μM) for 24 and 48h. Then, microglia activation was determined by the obvious
swelling and morphological changes of the OX-42 positive cells. After 24h of 100ng/ml
LPS exposure, 45% of the microglia were activated, and 60% microglia activation was
observed with 1μg/ml LPS (Figure 2.3). In contrast, pretreatment with pioglitazone, 1hr
before LPS, suppressed microglia activation to the control level (p<0.01). After 48h,
LPS activated ~80% of the microglia (Figure 2.4), and pretreatment with pioglitazone
(1μM and 10μM) significantly suppressed microglial activation within 50% and 30%,
respectively. In addition, the suppressive effect of pioglitazone (10μM) on the LPSinduced microglia proliferation is observed in primary microglia-enriched cultures after
48h LPS exposure (Figure 2.5).
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Figure 2. 3 Pioglitazone inhibits microglia activation in rat microglia-enriched cultures
(24hr).
Twenty four hours after seeding (2×105 cells/well) into 24-well plates, cultures were
treated with LPS (0.1 μg/ml–1 μg/ml) for 24h, and immunostaining for OX-42 was done.
A: Microglia in control (a) are small than in the LPS-treated group (b) (1 μg/ml), in
which the cells swelled, as represented by an arrow. The cell morphology did not change
in the pioglitazone alone group (c), and pretreatment with pioglitazone 10μM had less
swollen cells (d). B: The different doses of LPS activated 50%–60% of the microglia,
and pretreatment with pioglitazone (10μM) significantly attenuated microglia activation.
The data were expressed as the percentage of control and were the mean ± SEM, from
three independent experiments. (n=3) (**p<0.01 versus control; ##p<0.01 versus LPS).
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Figure 2. 4 Pioglitazone inhibits microglia activation in rat microglia-enriched cultures
(48hr).
Twenty four hours after seeding (2×105 cells/well) into 24-well plates, cultures were
treated with LPS (0.1μg/ml–1μg/ml) for 48h, and immunostaining with OX-42 was done.
A: In LPS-treated group (b), the immunostained cells become much bigger than control
group (a). An arrow in LPS-treated group indicates a typical activated microglia.
Pioglitazone alone did not change morphology of the cells (c), and pretreatment with
pioglitazone reduced the activated microglia (d), with some difference in their shape. B:
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Forty-eight hours of LPS exposure activated about 80% of the microglia in LPS group
(0.1μg/ml and 1μg/ml), and pretreatment with pioglitazone (1μM or 10 μM) significantly
reduced microglia activation. The data were expressed as the percentage of control and
were the mean ± SEM, from three independent experiments. (n=3) (**p<0.01 versus
control; ##p<0.01 versus LPS).

Figure 2. 5 Pioglitazone inhibits LPS-induced microglia proliferation (48hr).
Twenty four hours after seeding (2×105 microglia cells/well) into 24-well plates, cultures
were treated with LPS (1μg/ml) for 48 h, and immunostained with OX-42. Forty-eight
hours of LPS exposure increased the number of microglia, however, pretreatment with
pioglitazone (10μM) reduced microglia proliferation. The data were expressed as the
percentage of control and were the mean ± SEM, from three independent experiments.
(n=3) (*p<0.05 versus control; #p<0.05 versus LPS).
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Discussion
The results show that LPS neurotoxicity is microglia-dependent, and the PPARγ agonist
pioglitazone protects dopaminergic neurons against LPS insult via inhibiting microglia
activation. The current study shows that our in vitro cell culture system can be used as a
reasonable tool to further study the molecular mechanisms of neuroinflammationmediated dopaminergic neuronal death.
The brain has been considered as an immunological privileged site based on the
fact that blood-brain-barrier protects the brain from immune reaction.

However,

increasing evidence suggested that this postulation may have exceptions; especially under
the condition that microglia is excessively activated.

LPS-induced systematic

inflammation causing parkinsonism was reported from a case study (Niehaus et al., 2004),
in which a laboratory worker was contaminated with LPS (Salmonella minnesota,
10μg/ml) by wound in an accident and developed parkinsonism after three weeks
(Niehaus et al., 2004). Importantly, microglia activation but not reactive astrocytes has
been previously demonstrated in the SN of PD brains (McGeer et al., 1988b; Mirza et al.,
2000), and a growing body of evidence suggested that microglia activation could play a
critical role in mediating the survival of dopaminergic neurons in the PD midbrain (Ouchi
et al., 2005) as well as in animal models of Parkinson’s disease (Czlonkowska et al., 1996;
Lu et al., 2000; Le et al., 2001; Gao et al., 2002; Wu et al., 2002; Arai et al., 2004; Wang
et al., 2006; Hunter et al., 2007; Purisai et al., 2007).
The present study clearly demonstrates that LPS treatment of neuron-enriched
cultures fails to induce TH-positive cell loss, however, in the presence of microglia, a
dose-dependent TH-positive cell loss is observed with LPS treatment. This suggests that
the toxic effects of LPS on the mesencephalic dopaminergic neurons are dependent on
microglia activation and the subsequent release of proinflammatory factors, which is
consistent with the study from other labs (Liu et al., 2003; Qian et al., 2006; Mount et al.,
2007; Zhao et al., 2007). While the causal relationship of microglial activation and
dopaminergic neuron survival is still debatable, our finding that LPS failed to show
dopaminergic neurotoxicity in the absence of activated microglia supports the idea that
uncontrolled microglia activation can initiate dopaminergic neurodegeneration.
Pioglitazone significantly reduced the LPS-induced dopaminergic neuronal loss,
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suggesting its neuroprotective effect is related to its inhibiting microglia activation, which
can initiate neuronal loss by increasing proinflammatory factors such as superoxide, NO,
cytokines, and prostaglandins (Banati et al., 1993; Minghetti and Levi, 1998). The
protective effects of pioglitazone are in line with several previous studies that
demonstrated significant protection with pioglitazone in the MPTP PD model (Breidert et
al., 2002; Dehmer et al., 2004), experimental autoimmune encephalomyelitis (EAE)
model (Storer et al., 2005), transient cerebral ischemia model (Victor et al., 2006), and
LPS PD model (Hunter et al., 2007).
Traditionally, three classic types of microglia in terms of their morphology
(ameboid, ramified, and intermediate) was described according to observation from silver
carbonate staining developed 70 years ago (del Rio Hortega, 1932; Kershman, 1939).
With the gradual understanding of microglial function, the classification of microglia is
switched according to their activation condition: resting microglia, activated microglia,
and phagocytic microglia (Streit et al., 1989) . In our culture system, LPS increases the
ratio of activated microglia and pioglitazone inhibits their activation. On the other hand,
we observed that the total number of microglia, including activated and non-activated
microglia, is significantly less in the pioglitazone treated group in microglia-enriched
culture, suggesting pioglitazone suppresses LPS-induced microglia proliferation. Indeed,
it showed that the proliferation rate of microglia is increased upon LPS stimuli
(Shankaran, 2007), and the PPARγ agonist 15d-PGJ2 induces microglial death (Bernardo,
2003). However, two basic phenotypes of microglia were observed in the primary glial
cultures (Floden and Combs, 2007), and recently subsets of microglia in the mouse brain
were studied showing two cell groups with distinct ability to produce ROS (Nagatsu and
Sawada, 2006). It will be very informative to know the potential differential role of
PPARγ agonists in the microglia with different phenotypes, thus targeting the microglia
specifically detrimental to the dopaminergic neurons can be an effective strategy for PD
treatment.

Another interesting question is: By what mechanisms does pioglitazone

inhibit microglia proliferation? PGE2 is known to induce microglia death, probably via
its receptor EP2 and cAMP signaling, however, the present result showed that the
decrease in PGE2 level by pioglitazone is parallel with the decrease of microglia
proliferation.

Whether pioglitazone induces microglia death via modulating the
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expression of its cell cycle protein is interesting to be explored. Our result suggested that
the inhibitory effect of pioglitazone on microglia proliferation is LPS-dependent, since no
significant difference of microglia proliferation was observed between the control and
pioglitazone groups. The result is consistent with several studies, which demonstrated
that the PPARγ agonist BRL49653 induces significant macrophage apoptosis upon
cytokine TNF-α/IFNγ stimuli by DNA fragmentation assay (Chinetti et al., 1998) and
ciglitazone induces the death of activated microglia (Yang et al., 2006). Based on the
observation of LPS-dependent inhibition of proliferation in our experimental context, it is
reasonable to speculate that certain active molecule(s) released from activated microglia
take part in the PPARγ-mediated stress-dependent regulation on the microglia
proliferation.
In summary, our present results demonstrate that LPS neurotoxicity is microgliadependent, and pioglitazone protects dopaminergic neurons via suppressing microglia
activation and / or microglia proliferation.

In the next chapter (3), the underlying

mechanisms of LPS-induced dopaminergic neuronal loss and its interference by
pioglitazone were explored, focusing on the signaling transduction relevant to LPSinduced COX-2 / PGE2.
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CHAPTER 3: Neuroprotective effect of PPARγ activation with pioglitazone via
inhibiting COX-2 activity is associated with its inhibition of NF-kB and JNK
activation
(From published paper: B Xing., M Liu., GY Bing. (2007) J. Neuroimmunol. 192:89-98). M Liu took part
in the experiment in the immunocytochemistry.

Introduction
In Chapter 2, microglia-dependent LPS neurotoxicity was demonstrated, and it also
showed that the PPARγ agonist pioglitazone protects dopaminergic neurons against LPS
insult in our culture systems. The questions addressed in this chapter are: 1) the potential
inhibitive effect of pioglitazone on LPS-induced COX-2 / PGE2, and 2) the potential
interference of pioglitazone on the related signaling transduction pathways - NF-kB and
JNK.
A few postmortem studies demonstrated that the activity of NF-kB and COX-2
are significantly increased in the SN and striatum of PD brain (Hunot et al., 1997;
Teismann et al., 2003b).

The percentage of immunoreactive nuclear NF-kB in PD

midbrain is increased 70 fold compared to control samples (Hunot et al., 1997). The
microglial-related iNOS immunoreactivity in the PD SN and COX-2 / PGE2 level in
ventral midbrain are increased 3 fold compared to the control group (Teismann et al.,
2003b).
It is known that JNK and NF-kB are important mediators of inflammation
associated with COX-2 activity and its production of PGE2 (Uto et al., 2005; Won et al.,
2005; Nieminen et al., 2006). One study reported c-Jun activation in MPTP-induced PD
and in the dopaminergic neurons of PD patients, where deficiency of JNK prevented
neurodegeneration accompanied by a decrease in COX-2 expression (Hunot et al., 2004).
We have showed PPARγ agonism with pioglitazone protects SN dopaminergic
neurons against intrastriatal LPS insult, which was associated with COX-2 inhibition
(Hunter et al., 2007). In addition, pioglitazone protects dopaminergic neurons against
MPTP insult by inhibition of NF-kB (Breidert et al., 2002; Dehmer et al., 2004).
However, the effect of pioglitazone on JNK-mediated COX-2 and PGE2 generation upon
LPS insult has not been studied. The hypotheses in this chapter are: 1) pioglitazone
inhibits LPS-induced COX-2 expression and PGE2 synthesis; 2) pioglitazone protects
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dopaminergic neurons against LPS insult via inhibiting COX2 / PGE2 level by interfering
with NF-kB and JNK pathway. The specific aims are: 1) to test inhibitory effect of
pioglitazone on LPS-induced COX-2 expression by western blot, and PGE2 level by EIA
assay; 2) to measure the role of COX-2 inhibition in the survival of TH positive neurons
by using a selective COX-2 inhibitor CAY10404; 3) to test the inhibition of NF-kB / JNK
by pioglitazone using western blot analysis, and to test the role of NF-kB and JNK
inhibition in the LPS-induced PGE2 synthesis by using selective inhibitors.
Materials and methods
Animals
Twenty one timed-pregnant Sprague Dawley rats were obtained from Harlan
(Indianapolis, IN, USA) and were maintained in a strict pathogen free environment.
Animal use was performed in strict accordance with the National Institutes of Heath
guidelines and was approved by the Institute’s Animal Care and Use Committee at the
University of Kentucky.
Reagents
Salmonella minnesota LPS and pioglitazone were obtained from Sigma-Aldrich (St Louis,
MO, USA).

Selective inhibitors were as follows: T0070907-PPARγ inhibitor and

CAY10404–COX-2 inhibitor from Cayman (Ann Arbor, MI, USA), SP600125-JNK
inhibitor from A.G. Scientific (San Diego, CA, USA), and sulfasalazine-NF-kB inhibitor
from Sigma-Aldrich (St. Louis, MO, USA). Antibodies used were as follows: polyclonal
anti-tyrosine hydroxylase (TH) antibody from Pel-Freez Biologicals (Rogers, AR, USA),
polyclonal anti-COX-2 and polyclonal anti-NF-kB p65 from Cell Signaling (Danvers,
MA, USA), monoclonal anti-phospho-JNK antibody Santa Cruz (Santa Cruz, CA, USA),
and monoclonal anti-β-actin from Sigma-Aldrich (St. Louis, MO, USA). The other
reagents and culture medium were the same as those mentioned in chapter 2.
Mesencephalic neuron-microglia mixed cultures
The same methods were used as mentioned in chapter 2. Briefly, midbrain tissues were
dissected from day 14 SD rat embryos, dissociated via gentle mechanical trituration, and
the cells were seeded in poly D-lysine (50μg/mL) pre-coated 24-well plates (1x105/well)
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or in pre-coated 6-well plates for western blot (1x106 or 2x106 cells/well). Cells were fed
with DMEM/F12 containing 10% horse serum and 10% fetal bovine serum. Three days
after seeding, the cells were replenished with fresh medium.

At DIV6 or DIV7,

microglia were added into primary mesencephalic neuron-enriched cultures containing
1x105 cells/well, and after 24h, the cultures were treated with either pioglitazone or LPS
dissolved in DMSO, and the control groups were only treated with same amount of
DMSO (10μl).
Primary mesencephalic neuron-enriched cultures
Cultures were exposed to treatment seven days after seeding.
Microglia-enriched cultures
Primary glial cell cultures were established from cerebral cortices of 2-3 day-old neonatal
SD rats. Briefly, cerebral cortices were minced and gently dissociated. Cells were
collected by centrifugation and were cultured in 175cm2 cell culture flasks in 5% CO2 at
37°C. Floating microglia were harvested between 2-8 weeks, either seeded into 24-well
plates for primary microglia culture, or re-seeded back into 24-well plates (2x105) for
other assays. After 30mins, cultures were washed to remove non-adherent cells and fresh
medium was added, and the cultures were treated 24h after seeding.
Immunocytochemistry
Same as that mentioned in chapter 2, except the following: In the double-labeling of OX42 (1:1000) and NF-kB p65 (1:125), the color was developed with nickel-intensified 3,3'diaminobenzidine in Tris buffer during the final step.
PGE2 production
PGE2 in the supernatant was measured with a PGE2 EIA kit from Cayman (Ann Arbor,
MI, USA) according to the manufacturer’s instructions. The supernatant from primary
microglia-enriched culture (2x105cells/well) was measured for total PGE2 production.
The culture medium was removed for extracellular PGE2 measurement and 1ml PBS was
added into each well plate followed by sonication 3 times X 6 seconds for intracellular
PGE2 measure. For the PPARγ inhibition study, T0070907 (1nM) was added into culture
medium 1hr prior to either pioglitazone (10μM) and / or LPS (1μg/ml) treatment for 48hr.
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Western blot
Cells were collected and lysed for western blot analysis of COX-2, NF-kB and phosphoJNK.

Protein concentrations were determined with the bicinchoninic acid assay

following the manufacturer's guide. Equal amounts of protein were separated by a SDS
PAGE gel and were transferred to polyvinylidene difluoride membranes. Membranes
were blocked with 5% nonfat milk and incubated with polyclonal anti-COX2 antibody
(1:1000), polyclonal anti-NF-kB antibody (1:1000), and monoclonal anti-phospho-JNK
(1:1000) either for 1hr at room temperature or overnight at 4°C. Peroxidase-linked antirabbit or anti-mouse IgG (1:4000; 1hr at 25°C) and ECL-Plus reagents (Amersham
Biosciences Inc., Piscataway, NJ) were used as a detection system. The optical density
was measured using the scion imageTM software (Frederick, MD, USA).
Statistical Analysis
The data are expressed as the mean ± SEM and statistical significance was assessed by
ANOVA followed by a Tukey comparisons test using the SYSTAT 10 software (SPSS
Inc., Chicago, Illinois). A value of p < 0.05 was considered statistically significant. Data
presented represent three independent experiments.
Results
Pioglitazone inhibits LPS-induced COX-2 / PGE2 expression in microglia-enriched
cultures
PGE2 generated by COX-2 is a major component of the innate immune response.
Previous reports have shown that LPS strongly activates microglia, induces COX-2
expression, and enhances PGE2 synthesis (Bauer et al., 1997; Fiebich et al., 2003). In
this set of experiments, LPS-induced COX-2 expression was tested in the presence and
absence of pioglitazone. Western blot analysis revealed that COX-2 was undetectable
under basal conditions and with pioglitazone treatment, but COX-2 expression increased
with LPS treatment. The LPS-induced increase was suppressed by pretreatment with
pioglitazone (10μM) (Figure 3.1).

In addition, a 24hr LPS challenge (1μg/ml and

10μg/ml) induced a 50 and 100-fold induction of PGE2 (p<0.001), and pioglitazone
significantly attenuated PGE2 generation (p<0.01, Figure 3.2).
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Figure 3. 1 Pioglitazone inhibits LPS-induced COX-2 expression.
Primary mesencephalic cultures (1×106 cells/well) were treated with 1μg/ml LPS for 6 h,
and LPS treatment upregulated COX-2 expression.

Pretreatment with pioglitazone

(10μM) reduced COX-2 expression.

Figure 3. 2 Pioglitazone inhibits LPS-induced PGE2 synthesis in microglia-enriched
cultures.
In rat microglia-enriched cultures (2×105 cells/well), LPS (1μg/ml) increased PGE2 about
50 fold in 24h, and pretreatment with pioglitazone 1h prior to LPS administration
significantly decreased PGE2 generation. The data were expressed as the percentage of
control and were the mean ± SEM, from three independent experiments. (n=3) (**p<0.01
versus control; ***p<0.001 versus control; ##p<0.01 versus LPS).
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Inhibition of COX-2 protects dopaminergic neurons against LPS challenge
In order to confirm whether inhibition of COX-2 activity protects dopaminergic neurons
from LPS exposure, a selective COX-2 inhibitor (CAY10404, 1μM) was used in neuronmicroglia mixed culture, 1hr before a 96h LPS exposure. As shown in Figure 3.3,
inhibition of COX-2 protects dopaminergic neurons against LPS treatment (p<0.05).

Figure 3. 3 Inhibition of COX-2 protects dopaminergic neurons against LPS insult in rat
neuron-microglia mixed cultures.
Microglia (2×105 cells/well) were added back into neuron-enriched cultures (1×105
cells/well) at DIV6 along with 1 μM CAY10404 (a specific COX-2 inhibitor) 1 h before
a 96 h LPS (1μg/ml) treatment. TH-positive immunostained neurons were counted and
the results show that COX-2 inhibition protects the neurons. The data were expressed as
the percentage of control and were the mean ± SEM, from three independent experiments.
(n=3) (**p<0.01 versus control; #p<0.05 versus LPS).
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Suppression of PGE2 generation by pioglitazone is associated with interference with NFkB and JNK activity
Since both the JNK and NF-kB pathways are involved in the proinflammatory response
to LPS insult (Hambleton et al., 1996), we tested whether pioglitazone can suppress JNK
and NF-kB phosphorylation.

As shown in Figure 3.4, LPS (1μg/ml) increased the

amount of phosphorylated JNK (Thr-183 and Tyr-185) and phosphorylated NF-kB (p65
at ser276).

In contrast, pioglitazone treatment, 1hr before LPS, inhibited the

phosphorylation of JNK and NF-kB (p<0.05).

To investigate our hypothesis that

pioglitazone inhibits NF-kB nuclear translocation in microglia, immunostaining of OX42 (an indicator for microglia) and phosphorylated NF-kB p65 was performed in primary
mesencephalic culture, and NF-kB nuclear translocation was observed in microglia upon
LPS (1μg/ml) treatment (Figure 3.5 b).

In contrast, pretreatment with pioglitazone

suppressed NF-kB nuclear translocation (Figure 3.5 d).
To further determine if inhibition of JNK or NF-kB leads to the suppression of
PGE2 generation, sulfasalazine, a selective NF-kB inhibitor, and SP600125, a selective
JNK inhibitor, were used in microglia-enriched cultures, 1hr before LPS treatment
(1μg/ml and 10μg/ml). As shown in Figure 3.6, a 50 and 130-fold increase in PGE2
generation were found, respectively (p<0.01 or p<0.001).

Pretreatment with

sulfasalazine (10μg/ml) or SP600125 (5μM) significantly suppressed PGE2 generation
after a 24h LPS exposure (p<0.01).
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Figure 3. 4 Pioglitazone inhibits LPS-induced phosphorylation of JNK and NF-kB in
neuron-microglia mixed cultures.
A: Microglia were added back into neuron-enriched cultures, and increased
phosphorylated JNK and NF-κB were found upon 1μg/ml LPS exposure. Pretreatment
with pioglitazone (10μM), for 1 h, inhibited JNK phosphorylation (Thr-183 and Tyr-185)
and NF-κB p65 (Ser276) phosphorylation.

B and C: Densitometric measurements

showed LPS-induced increased JNK (B) and NF-kB (C) phosphorylation and inhibition
by pioglitazone. The data were expressed as the percentage of control and were the mean
± SEM, from three independent experiments. (*p<0.05 versus control; #p<0.05 versus
LPS).
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Figure 3. 5 Pioglitazone inhibits NF-kB nuclear translocation in microglia upon LPS
stimuli.
Primary mesencephalic cultures (1×105 cells/well) were immunostained with anti-OX-42
antibody (1:1000), followed by anti-NF-κB p65 (1:125) staining. In the control group,
NF-κB p65 staining (dark blue) was in the cytoplasm (a), however, sixty minutes of LPS
(1μg/ml) exposure induced NF-κB p65 nuclear translocation, as shown by the arrow in
(b). Both the pioglitazone group (c) and pioglitazone plus LPS group (d) showed that
NF-κB p65 staining was in the cytoplasm, rather than the nucleus, suggesting that
pretreatment with pioglitazone 1 h before LPS treatment suppressed NF-κB nuclear
translocation.
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Figure 3. 6 Inhibition of NF-kB and JNK reduces PGE2 generation in microglia-enriched
cultures.
Microglia-enriched cultures (2×105 cells/well) were treated 24 h after seeding, and a 24h
LPS (1μg/ml) treatment induced PGE2 generation in a dose-dependent manner. The NFkB inhibitor (Sulfasalazine) or JNK inhibitor (SP600125) was added 1 h before the LPS
treatment and the LPS induced PGE2 generation was significantly reduced. The data
were expressed as the percentage of control and were the mean ± SEM, from three
independent experiments. (n=3) (**p<0.01 versus control; ***p<0.001 versus control;
##p<0.01 versus LPS 1μg/ml).
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A PPARγ antagonist failed to reverse pioglitazone inhibition of LPS-induced PGE2
generation in primary microglia-enriched culture
Our preliminary study suggested that PGE2 generation induced by LPS is PPARγindependent. In order to investigate the possibility that pioglitazone inhibition of LPSinduced PGE2 might be PPARγ-dependent in terms of intracellular and extracellular
PGE2, a highly selective antagonist T0070907 was used in the primary microgliaenriched culture. Forty-eight hour exposure to LPS (1μg/ml) stimuli induced a ~20 fold
increase in the extracellular PGE2 level, and pretreatment with pioglitazone significantly
inhibited it (Figure 3.7 A, p<0.05), however, T0070907 (1nM) failed to show reversing
effect on the inhibition of LPS-induced PGE2 by pioglitazone. The similar response
pattern was observed to measure intracellular PGE2 level, and pioglitazone decreased its
level, however, pretreatment with T0070907 (1nM) did not show its reversing effect on
the PGE2 inhibition by pioglitazone (Figure 3.7 B).
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Figure 3. 7 Effect of T0070907 on the pioglitazone inhibition of LPS-induced PGE2
generation.
Primary microglia-enriched culture (2x105/well) was treated with T0070907 (1nM) either
alone or plus pioglitazone (10μM) and / or LPS (1μg/ml) for 48hr, then extracellular and
intracellular PGE2 levels were measured (Figure 3.7 A and B). A: (extracellular PGE2)
Pioglitazone inhibited LPS-induced PGE2 levels, pretreatment with T0070907 did not
block the inhibition of LPS-induced PGE2 production by pioglitazone. B: (intracellular
PGE2) a similar pattern was found. Pretreatment with T0070907 (1nM) failed to reverse
pioglitazone inhibition of LPS-induced PGE2. The data were expressed as the percentage
of control and were the mean ± SEM, from three independent experiments. (n=3)
(**p<0.01 versus control; #p<0.05 versus LPS; ##p<0.01 versus LPS).
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Discussion
In the previous chapter, our results showed that pioglitazone protects dopaminergic
neurons against LPS neurotoxicity via inhibiting microglia activation.
In this chapter, LPS-induced COX-2 and PGE2 was emphasized, and the potential
interference of the relevant signaling pathways with pioglitazone was investigated. In
addition, the potential inhibition of PGE2 by pioglitazone was explored. The present in
vitro study demonstrates that the neuroprotective effects of pioglitazone are associated
with inhibiting JNK and NF-kB pathways, which inhibits the inflammatory reaction by
attenuating the expression of COX-2 and PGE2 generation, resulting in the survival of
dopaminergic neurons. In addition, it appears that the inhibition of PGE2 synthesis by
pioglitazone might not be PPARγ-dependent.
COX-2 has been suggested as a key element in the pathological process of PD.
COX-2 expression in the ventral midbrain of PD brain samples is increased (Teismann et
al., 2003b) and COX-2 inhibition or deficiency protects dopaminergic neurons against
MPTP and 6-OHDA toxicity (Teismann and Ferger, 2001; Sanchez-Pernaute et al., 2004;
Vijitruth et al., 2006). Our LPS in vitro PD model demonstrated that pioglitazone
inhibits COX-2 expression (Hunter et al., 2007).

The present study reports that

pioglitazone inhibits LPS-induced COX-2 in the primary mesencephalic-microglia mixed
culture and PGE2 synthesis in microglia. Combined with the observation that LPS
neurotoxicity is microglia-dependent described in chapter 2 and inhibition of COX-2
rescues the neurons, the results suggest that microglia-derived PGE2 may play an
important role in the detrimental process of dopaminergic neuronal death, and
pioglitazone provides beneficial effects via inhibiting its synthesis.

Although the

underlying mechanisms of cellular PGE2–induced neurotoxicity in human are not known,
the distribution of PGE2 receptors (EP1, 2, 3, and 4) in rat midbrain and the potential
PGE2 receptor-mediated neurotoxicity in 6-OHDA in vitro model was investigated
(Carrasco et al., 2007).

Their studies identified EP1 and EP2 receptors on the

dopaminergic neurons by immunohistochemistry for TH and PGE2 receptors.
Interestingly, only activation of EP1 receptor is toxic to dopaminergic neurons, in
agreement with the similar toxicity induced by PGE2 treatment. In contrast, selective
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antagonist for EP1 receptor rescues dopaminergic neurons against 6-OHDA insult in
primary mesencephalic neuronal cultures.
Based on the aforementioned reports, pioglitazone protects dopaminergic neurons
probably via inhibiting LPS-induced PGE2 synthesis. In addition, pioglitazone might
also regulate EP1 receptor activity to attenuate PGE2-mediated toxicity. Indeed, this
could be possible since a PPARβ agonist increased EP4 mRNA and protein levels in
human lung carcinoma cell line (Han et al., 2005).
Further study on the NF-kB and JNK activity in mixed cultures showed that
pioglitazone suppresses their phosphorylation and NF-kB nuclear translocation induced
by LPS.

In addition, inhibition of NF-kB and JNK activity decreases PGE2 level,

suggesting not only NF-kB but also JNK mediate COX-2 activity, which is the first
report demonstrating LPS-induced COX-2-mediated dopaminergic neuronal death in
vitro model is associated with increased JNK activity.
Increased NF-kB immunoreactivity and expression were observed in the midbrain
of PD patients (Hunot et al., 1997; Mogi et al., 2007). The current study showed that
pioglitazone inhibits LPS-induced NF-kB phosphorylation and microglial nuclear
translocation, in agreement with the study on the pioglitazone neuroprotection in MPTP
animal model (Dehmer et al., 2004). The underlying mechanisms of the inhibitory effect
of NF-kB activity by PPARγ agonists are not clearly known due to the wide spectrum of
gene transcriptions regulated by both PPARγ and NF-kB.

However, results from

different cell culture systems suggested that PPARγ agonists including synthetic ligands
inhibit NF-kB activation via PPARγ-independent mechanisms. For example, the PPARγ
agonist 15d-PGJ2 inhibits the LPS-induced degradation of IkBα in RAW264.7 cells
which only express very low PPARγ (Straus et al., 2000; Castrillo et al., 2001).
The direct implication that JNK activation may be related to the death of
dopaminergic neurons came from the observation that the JNK inhibitor CEP-1347
protected neurons against MPTP toxicity (Saporito et al., 1999). Further results from an
experimental PD model provided a link between the activation of JNK activation / COX2 expression and survival of dopaminergic neurons. In their studies, MPTP increased cJUN phosphorylation in the midbrain, in contrast, the JNK inhibitor CEP-11004 or JNK
deficiency suppressed its expression accompanied with a decreased COX-2 expression
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(Teismann et al., 2003b; Hunot et al., 2004). In the midbrain slice culture system,
inhibition of JNK activity protects dopaminergic neurons against LPS/IFNγ insult
(Shibata et al., 2006). It was suggested that MPTP activates the JNK signaling cascade,
and JNK kinase (MKK4) / JNK / c-Jun / caspase-3 sequential activation is involved in
dopaminergic neuronal death (Xia et al., 2001). Further study on the interference of JNK
signaling-mediated neuronal loss by pioglitazone will be informative to understand its
underlying protective mechanisms.
It is worth noting that T0070907, a highly selective PPARγ antagonist (Lee et al.,
2002), has generated great interest recently as it is more potent and selective (with its IC50
1nM for rosiglitazone) than other antagonists such as GW9662. We used T0070907 to
test if the inhibition of LPS-induced PGE2 generation by pioglitazone is PPARγdependent.

Under current experimental condition, no significant blocking effect of

T0070907 on the inhibition of PGE2 by pioglitazone was observed in the measurement of
both intracellular-PGE2 and excellular-PGE2 levels, suggesting pioglitazone might
suppress LPS-induced PGE2 in a PPARγ-independent manner. One study on the PGE2
synthesis in lung cancer cell line revealed PPARγ-independent mechanisms since the
PPARγ antagonist GW9662 did not block pioglitazone-mediated inhibition of PGE2
generation (Hazra et al., 2007). On the other hand, another study on the TNFα-induced
PGE2 production in human smooth muscle cell culture demonstrated a PPARγ-dependent
effect (Ringseis et al., 2006). Since pioglitazone inhibits PGE2 synthesis partially via
inhibiting NF-kB, which can be inhibited by PPARγ agonists via receptor-independent
mechanisms (Straus et al., 2000; Castrillo et al., 2001), the PPARγ-independent inhibition
of PGE2 in our cell culture system may be related to the PPARγ-independent inhibition of
NF-kB. PPARγ knockdown will be very helpful to address if its inhibitive effect on
PGE2 is receptor-dependent or independent.
The aforementioned studies indicate that the neuroprotective effects of
pioglitazone are associated with its blocking multiple proinflammatory signaling
pathways, including NF-kB and JNK pathways. However, its potential inhibitory effect
on microsomol PGE synthase-1 (mPGES-1), which is the enzyme converting PGD2 to
PGE2, cannot be ruled out, since LPS administration in vivo and in vitro causes persistent
upregulation of mPGE-1 (Devaux et al., 2001; Ajmone-Cat et al., 2003). In addition,
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activation of PPARγ blocked the up-regulation of COX-2, mPGES-1, and PGE2 in mouse
embryo fibroblasts (Kapoor et al., 2007). Therefore, in the future, it would be very
interesting to determine if pioglitazone influences mPGES-1 activity in our cell culture
systems.
In summary, the studies described in the current chapter suggest that the
neuroprotective effects of pioglitazone are associated with the inhibition of JNK and NFkB pathways as well as with the suppression of COX-2 activity and decreased PGE2
generation, probably via PPARγ-independent mechanisms.

This ultimately protects

dopaminergic neurons via attenuating microglia-mediated and inflammation-induced
neurodegeneration.
In the next chapter 4, LPS-induced iNOS / NO and its inhibition by pioglitazone
via suppression of p38 MAPK signaling pathway will be emphasized.

Copyright © Bin Xing 2008
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CHAPTER 4: Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide
synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt
(From published paper: B Xing, T Xin, RL Hunter, GY Bing. (2008) J. Neuroinflammation 5:4). T Xin took
part in Western blot; RL Hunter took part in experimental design.

Introduction
Chapter 2 demonstrated that LPS neurotoxicity is microglia-dependent, and pioglitazone
protects dopaminergic neurons via inhibiting microglia activation. In chapter 3, the study
suggested that pioglitazone protects dopaminergic neurons against LPS insult by
suppressing COX-2 expression and PGE2 synthesis via interfering with NF-kB and JNK
pathways. In this chapter, LPS-induced iNOS and NO generation are emphasized, and
the following questions are discussed: 1) the inhibitory effects of pioglitazone on LPSinduced iNOS and NO production; 2) the potential differential role of p38 MAPK and
JNK pathway in the LPS-induced NO generation; 3) the potential differential mediation
of p38 MAPK and JNK by pioglitazone; 4) the potential mediation of PI3K / Akt activity
by pioglitazone and its effect on NO generation.
One of the major effectors responsible for neurodegeneration is NO. Under
normal condition, NO is a necessary component for synaptic transmission (Bredt, 1999).
Under pathological condition, however, excessive NO can react with superoxide and
form the lipid-permeable oxidant peroxynitrite which can directly oxidize proteins, lipids,
and DNA. In addition, peroxynitrite can disrupt mitochondria function (Brown, 1999)
and is related to mitochondria-driven reactive oxygen and reactive nitrogen species
production (Poderoso et al., 1996), ultimately resulting in cell death.
Twenty years ago, postmortem analysis revealed that a great number of activated
microglia surround dopaminergic neurons in the SN of PD brain samples (McGeer et al.,
1988b).

Recent postmortem studies provided evidence on the detrimental role of

activated microglia-mediated iNOS / NO in dopaminergic neuron degeneration. In their
studies upregulated microglial iNOS expression was observed in the SN of PD brain
(Hunot et al., 1996; Knott et al., 2000). The experimental studies demonstrated that
increased iNOS activation is associated with the death of dopaminergic neurons in vitro
(Okuno et al., 2005; Lin et al., 2007) and in vivo (Liberatore et al., 1999; Teismann and
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Ferger, 2001; Arimoto and Bing, 2003).

In contrast, inhibition of iNOS showed

neuroprotection toward dopaminergic neurons against toxic insults (Wang et al., 2002;
Katsuki et al., 2006).
p38 MAPK and JNK pathways are two main signaling cascades modulating
inflammatory response and stress (Kyriakis and Avruch, 2001). Experimental in vitro
study suggested that activation of p38 MAPK is involved in LPS-induced insults in glial
cells (Bhat et al., 1998). Activated microglia-induced cortical neuronal death has been
attributed to p38 MAPK activation (Xie et al., 2004), and inhibition of p38 MAPK
activity rescued dopaminergic neurons from a thrombin-activated microglia insult (Lee et
al., 2005). Recent LPS in vitro and in vivo studies strongly implicated a role of p38
MAPK in the LPS-induced microglia-mediated dopaminergic neuronal loss. Inhibition
of p38 MAPK pathway by its inhibitor protected neurons and NO production in the
primary mesencephalic culture was decreased (Jeohn et al., 2002). The other study
showed that intranigral co-injection of LPS with p38 MAPK inhibitor rescued
dopaminergic neurons in the SN, accompanied with reduced iNOS expression (Ruano et
al., 2006). In contrast, the role of the JNK pathway in the LPS model is less studied. The
result from a midbrain slice culture study suggested that inhibition of JNK activity
rescues LPS/IFNγ-induced dopaminergic neuronal loss without influencing iNOS
expression (Shibata et al., 2006). However, in their studies the role of astrocytes was not
ruled out, and the potential role of JNK pathway in the mediation of LPS-induced NO
were not tested.
One study on mouse peritoneal macrophages demonstrated that the PPARγ
agonist 15d-PGJ2 suppresses IFN-γ-induced iNOS protein and its mRNA (Ricote et al.,
1998). An in vivo study demonstrated that the PPARγ agonist troglitazone suppresses
cerebellular iNOS expression and protected cerebellular granule cells against LPS/IFN-γ
insult (Heneka et al., 2000).

A very recent study on the experimental PD model

demonstrated that the PPARγ agonist pioglitazone protected dopaminergic neurons from
MPTP insult, and iNOS-positive microglial cells were suppressed (Breidert et al., 2002);
further study from the same research group suggested that pioglitazone protected TH
positive neurons against MPTP insult probably via PPARγ activation and suppression of
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iNOS expression (Dehmer et al., 2004). However, whether the inhibition of iNOS by
pioglitazone is PPARγ-dependent or PPARγ-independent is still not defined.
The above studies strongly suggested that PPARγ agonists protect dopaminergic
neurons via inhibiting microglial iNOS expression. However, several questions remain
to be addressed. First, the role of pioglitazone in mediating LPS-induced NO production
in microglia has not been studied; Second, the role of pioglitazone in the LPS-induced
p38 MAPK pathway have not been investigated. So, the first hypothesis in this chapter is
that pioglitazone inhibits LPS-induced NO generation probably via interference with p38
MAPK and JNK pathways. The first specific aim is to test 1) the inhibitory effect of
pioglitazone on LPS-induced NO generation (by nitrite assay) in primary microglia
cultures and iNOS expression (by western blot) in mixed cultures, 2) the inhibitory effect
of pioglitazone on LPS-induced p38 MAPK in mixed cultures (by western blot), 3) the
effect of p38 MAPK and JNK inhibition on NO production in microglia by using their
selective inhibitors, and 4) if the inhibition of LPS-induced NO generation by
pioglitazone is PPARγ-dependent or PPARγ-independent.
PI3K / Akt is a well-known cell survival signaling pathway (Brazil and
Hemmings, 2001). Neurotrophic factors such as nerve growth factor promote neuronal
survival via activating the PI3K/Akt cascade (Halvorsen et al., 2002; Nusser et al., 2002;
Bonnet et al., 2004; Zhou et al., 2004; Yoshii and Constantine-Paton, 2007). On the
other hand, PI3K/Akt mediates both the apoptosis and inflammatory responses (Cantley,
2002). Inhibition of PI3K by LY294002 promoted MPP+-induced SH-SY5Y apoptosis,
and activation of Akt can protect cells (King et al., 2001). Nerve growth factor treatment
prevented

MPP+-induced

SH-SY5Y

apoptosis

possibly

via

increasing

the

phosphorylation of PI3K / Akt (Halvorsen et al., 2002). Recent studies demonstrated that
the PI3K/Akt pathway inhibits the inflammatory response in monocytes via inhibiting the
JNK and p38 MAPK pathways (Guha and Mackman, 2002). It is interesting to know if
PI3K differentially mediates p38 MAPK and JNK activity inhibiting LPS-induced NO.
Although the potential effects of PPARγ agonists on the PI3K activity have not been
studied, one study on the LPS-induced iNOS in mucous acinar cells demonstrated that the
PPARγ agonist ciglitazone inhibited its expression and inhibition of PI3K countered its
inhibitive effect (Slomiany and Slomiany, 2003). Whether pioglitazone alters the activity
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of PI3K/Akt pathway and thus inhibits LPS-induced NO is a very interesting question.
The second hypothesis is that 1) the PI3K pathway takes part in LPS-induced p38 MAPK
/ JNK activation; 2) pioglitazone alters activation of the PI3K/Akt pathway. The second
aim is to test 1) if inhibition of PI3K activity increases LPS-induced p38 MAPK and JNK
phosphorylation (western blot), by using the PI3K selective inhibitor wortmannin; 2) if
inhibition of PI3K increases LPS-induced p38 MAPK-mediated NO production in
primary microglia culture (nitrite assay); and 3) if PI3K / Akt activity is altered by
pioglitazone treatment (western blot).
Methods
Animals
Thirty two timed-pregnant Sprague Dawley rats were obtained from Harlan (Indianapolis,
IN, USA), and maintained in a pathogen-free environment. Housing, breeding, and
experimental use of the animals were performed in strict accordance with the National
Institutes of Heath guidelines and were approved by the Institute’s Animal Care and Use
Committee at the University of Kentucky.
Reagents
Same as these mentioned in chapter 2 and 3 except the following: T0070907-PPARγ
antagonist and 1400W-iNOS inhibitor from Cayman Chemical (Ann Arbor, MI, USA),
SP600125-JNK inhibitor and SB203580-p38 inhibitor from A.G. Scientific (San Diego,
CA, USA), and wortmannin-PI3K inhibitor from Sigma-Aldrich. Antibodies: polyclonal
anti-iNOS from Millipore (Billerica, MA, USA), monoclonal anti- phospho p38 from
Cell Signaling (Danvers, MA, USA), monoclonal anti-PPARγ (ser473) from Upstate
(Billerica, MA, USA), polyclonal anti-PI3K p110 and polyclonal anti-Akt (Thr308) from
Santa Cruz (Santa Cruz, CA, USA).
Mesencephalic neuron-microglia mixed cultures
Same as that mentioned in chapters 2 and 3.
Primary mesencephalic neuron-enriched cultures
Same as that mentioned in chapters 2 and 3.
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Microglia-enriched cultures
Same as that mentioned in chapters 2 and 3.
Nitrite oxide assay
The production of NO was assessed by the accumulation of nitrite in culture supernatants
by using the colorimetric reaction of the Griess reagent. Culture supernatants were
collected at different time points following LPS stimulation and were mixed with Griess
reagent (0.1% N-[1-naphthyl] ethylenediamine dihydrochloride, 1% sulfanilamide, and
2.5% H3PO4). The absorbance at 548nm was measured with a spectraMAX microplate
reader from Molecular Devices (Sunnyvale, CA, USA). For the PPARγ inhibition study,
T0070907 (1nM) was added into the culture medium 1hr prior to either pioglitazone
(10μM) and / or LPS (1μg/ml) treatment for 48hr.
Western blot
Same as that described in chapters 2 and 3 except different antibodies were used. The
antibodies and their concentrations used in western blot are: Polyclonal anti-iNOS
antibody (1:1000), monoclonal anti-p38 (1:2000), monoclonal anti-PPARγ (1:250),
polyclonal anti-PI3K p110 (1:250), and polyclonal anti-Akt (1:250).
Statistical analysis
The data are expressed as the mean ± SEM and statistical significance was assessed by
ANOVA followed by a Tukey comparisons test using the SYSTAT 10 software (SPSS
Inc., Chicago, Illinois). A value of p<0.05 was considered statistically significant.
Results
Pioglitazone inhibits LPS-induced nitric oxide generation in microglia-enriched cultures
To determine the effect of the PPARγ agonist pioglitazone on NO generation, two
different doses of pioglitazone (1μM and 10μM) were administered to microglia-enriched
cultures 1hr before LPS (1μg/ml) treatment. LPS induced a 4-fold increase in NO
generation (p<0.001) after 48hr, and pretreatment with pioglitazone reduced NO
production by about 40% to 60% (p<0.001), respectively (Figure 4.1).

However,

administration of pioglitazone concurrent with LPS, or 1hr after LPS, failed to inhibit the
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LPS-induced NO increase (Figure 4.2). In addition, pioglitazone alone did not alter NO
production.

Figure 4. 1 Pioglitazone inhibits LPS-induced NO production in microglia-enriched
cultures.
Microglia cultures (2x105 cells/well) were treated with pioglitazone (1 μM and 10μM) 1
hr before LPS treatment, and 48 h later NO levels were measured. LPS significantly
induced NO generation, and pretreatment with pioglitazone inhibited this LPS-induced
NO production in a dose-dependent manner. The data were expressed as the percentage
of control and were the mean ± SEM, from three independent experiments. (n=3) (***p <
0.001 versus. control; ###p < 0.001 versus. LPS)
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Figure 4. 2 Post-treatment of pioglitazone did not show inhibition of LPS-induced NO
production in microglia-enriched cultures
Pioglitazone was added with LPS at the same time or 1 hr after LPS treatment in
microglia-enriched cultures (2x105 cells/well), and 48 h later NO levels were measured.
A: pioglitazone was added with LPS at the same time. B: pioglitazone was added 1h after
LPS treatment. In both A and B, LPS significantly induced NO generation, however, no
inhibitory effect of NO was observed. The data were expressed as the percentage of
control and were the mean ± SEM, from three independent experiments. (n=3) (***p <
0.001 versus. control)
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Pioglitazone inhibits LPS-induced iNOS expression, and iNOS inhibition protects
dopaminergic neurons from LPS insults in mesencephalic mixed cultures
In this set of experiments, iNOS expression was determined by western blot performed
48h after LPS (1μg/ml) treatment. As shown in Figure 4.3, basal iNOS expression was
decreased by pioglitazone (p<0.001), LPS treatment produced significantly enhanced
iNOS expression (p<0.01), and pretreatment with pioglitazone (10μM) significantly
reduced this LPS-induced increase in iNOS expression (p<0.01). In addition, we used
immunocytochemistry for TH-positive cells to assess the effect of a specific iNOS
inhibitor, 1400W (1nM to 10μM), on the survival of dopaminergic neurons 72hr after
LPS treatment. Figure 4.4 shows that LPS induces a significant loss (90%) of the THpositive neurons when the iNOS inhibitor is administered 1hr before LPS (1μg/ml).
Partial neuroprotection against the LPS insult was seen when using 1400W at 100nM
(p<0.05) and 1μM (p<0.001).

Figure 4. 3 Pioglitazone inhibits LPS-induced iNOS expression.
Rat mesencephalic mixed cultures (2x106cells/well) were treated with 1 μg/ml LPS for 48
hours.

LPS treatment upregulated the expression of iNOS, and pretreatment with

pioglitazone (10 μM), 1 hr before LPS, prevents its expression. The data were expressed
as the percentage of control and were the mean ± SEM, from three independent
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experiments. (n=3) (**p < 0.01 versus. control, ***p < 0.001 versus. control, ##p < 0.01
versus. LPS).

Figure 4. 4 iNOS inhibition protects dopaminergic neurons from LPS insults.
Rat mesencephalic mixed cultures (2x105 microglia added) were treated with the
selective iNOS inhibitor 1400 W, with different doses from 1 nM to 1μM, 1 hr before a
72 hr LPS exposure.

The number of TH-positive neurons was determined by

immunocytochemistry. The data were expressed as the percentage of control and were
the mean ± SEM, from three independent experiments. (n=3) (***p < 0.001 versus.
control, #p < 0.05 versus. LPS, ###p < 0.001 versus. LPS).

57

Pioglitazone reduces NO levels by inhibition of p38 MAPK activity
In this set of experiments, pretreatment with pioglitazone (10μM) 1hr before LPS
(1μg/ml) decreased phosphorylation of p38 MAPK (Figure 4.5), and pretreatment with
wortmannin (1μM and 10μM) increased LPS-induced p38 MAPK phosphorylation in a
dose-dependent manner (Figure 4.6 A-C. p<0.05). An increase in phosphorylation of
p38 MAPK was not found when wortmannin was administered alone, without LPS
stimuli (Figure 4.6 D). Wortmannin also did not change JNK expression (Figure 4.6 A
and C).

In addition, two proinflammatory pathways were examined, in order to

demonstrate their involvement in the LPS-induced increase in NO production. Either
SB203580 (a selective p38 MAPK inhibitor) or SP600125 (a selective JNK inhibitor)
was administered to microglia-enriched cultures 1hr before LPS (1μg/ml) exposure. As
shown in Figure 4.7, LPS significantly increased NO generation (p<0.001) and inhibition
of p38 MAPK activity by pretreatment with SB203580 (5μM) decreased this NO
production (p<0.05).
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Figure 4. 5 Pioglitazone inhibits LPS-induced p38 MAPK activity.
Pretreatment with pioglitazone inhibited LPS-induced phosphorylation of p38 MAPK in
mesencephalic neuronal-microglia mixed cultures. Pioglitazone was added 1 hr before
LPS treatment (1 μg/ml) and p38 MAPK was immunobloted.

LPS increased

phosphorylation of p38 MAPK, and pretreatment with pioglitazone inhibited this
expression. The data were expressed as the percentage of control and were the mean ±
SEM, from three independent experiments. (*p < 0.05 versus. control, #p < 0.05 versus.
LPS).
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Figure 4. 6 Inhibition of PI3K activity increases LPS-induced p38 MAPK activity upon
LPS stimuli.
Wortmannin (1 μM and 10 μM) was administered to mesencephalic neuron-microglia
mixed cultures alone or before LPS (1 μg/ml) was added and, after 30 mins, p-JNK and /
or p-p38 MAPK was immunobloted. A: In the absence of LPS stimuli, inhibition of
PI3K did not increase p38 MAPK phosphorylation. B: Upon LPS stimuli, inhibition of
PI3K increases p38 MAPK phosphorylation rather than JNK phosphorylation. C:
Densitometric measurements showed that in the presence of LPS stimuli, inhibition of
PI3K increased p38 MAPK phosphorylation. D: Densitometric measurements showed
that in the presence of LPS stimuli, inhibition of PI3K did not increase JNK
phosphorylation. The data were expressed as the percentage of control and were the
mean ± SEM, from three independent experiments. (*p < 0.05 versus. wortmannin 1μM
plus LPS).
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Figure 4. 7 Inhibition of p38 MAPK decreases LPS-induced NO generation in microgliaenriched cultures.
A selective p38 MAPK inhibitor (SB203580), or a selective JNK inhibitor (SP600125),
was added to microglia-enriched cultures 1 hr before LPS (1 μg/ml) exposure and, after
24 h, NO levels were measured. The inhibition of LPS-induced NO was only found
using SB203580. The data were expressed as the percentage of control and were the
mean ± SEM, from three independent experiments. (n=3) (***p<0.001 versus control;
#p<0.05 versus LPS)
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The alteration of PPARγ activity is not shown in primary neuron-enriched cultures upon
pioglitazone treatment and LPS insult
As shown in Figure 4.8, in primary neuron-enriched culture, activation of PPARγ by
pioglitazone is not observed.

Figure 4. 8 Activation of PPARγ by pioglitazone is not observed in the primary neuronenriched culture.
Primary neuron-enriched cultures (2 × 106 cells/well) were treated with pioglitazone (10
μM) 1 hr before LPS (1 μg/ml) exposure. PPARγ activation was assessed after 10 min.
PPARγ activation was not observed in the both pioglitazone- and LPS-treated group. The
data were from three independent experiments. (c=control, L1=LPS (1 μg/ml), P10
=pioglitazone (10 μM)).

Inhibition of PI3K activity prevents the inhibitory effect of pioglitazone on LPS-induced
NO production and pharmacological inhibition of PPARγ activity increases LPS-induced
NO level
To determine if pioglitazone enhances PI3K/Akt expression and if its inhibition enhances
LPS-induced NO generation, the levels of PI3K and Akt were determined. PPARγ, PI3K,
and Akt phosphorylation were measured after LPS (1μg/ml) exposure. As shown in
Figure 4.9, PPARγ activation was observed in pioglitazone-treated cultures within 10min
after DMSO or LPS. PI3K and phosphorylated Akt were increased 60min after LPS in
the pioglitazone-treated cultures (p<0.05). Next, wortmannin (1μM) was added 30mins
before pioglitazone (10μM) treatment and the NO level was measured 48h after LPS
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(1μg/ml). The results showed that pretreatment with pioglitazone inhibited the LPSinduced NO increase (Figure 4.10, p<0.01). However, when wortmannin was given
30mins before pioglitazone, NO production was increased over LPS exposure (p<0.05).
Interestingly, administration of wortmannin (1μM) 30min before pioglitazone followed
by LPS 1hr later did not show the inhibitive effect of pioglitazone on NO level.
Wortmannin alone, or together with pioglitazone, did not influence NO generation
without LPS stimulation. Thus, pioglitazone prevents LPS-induced NO production, and
pretreatment with wortmannin increases NO generation (Figure 4.10). As shown in
Figure 4.11, pretreatment with T0070907 (1nM) reverses the inhibitive effect of
pioglitazone on the LPS-induced NO production (p<0.001).

Figure 4. 9 Pioglitazone activates PPARγ and enhances PI3K/Akt activity.
Rat mesencephalic cultures (2 × 106 cells/well) were treated with pioglitazone (10 μM)
only, or 1 hr before LPS (1 μg/ml) exposure. A: PPARγ activation was assessed after 10
min, and P13K and Akt were assessed after 60 min. PPARγ activation, PI3K and Akt
expression were observed in the pioglitazone-treated cultures, compared to control and
LPS alone groups.

B: Densitometric measurements showed that the expression of

phosphorylated PPARγ, PI3K, and Akt is higher than control group and LPS alone group.
The data were expressed as the percentage of control and were the mean ± SEM, from
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three independent experiments. (*p < 0.05 versus. control, #p < 0.05 versus. LPS, ##p <
0.01 versus. LPS).

Figure 4. 10 PI3K negatively regulates the LPS-induced increase in NO production.
The specific PI3K inhibitor wortmannin (1 μM) was administered individually 90 mins
before LPS treatment (1 μg/ml), or 30 mins before pioglitazone followed by LPS 60 mins
later in microglia-enriched culture, and after 48 h NO levels were measured. The results
show that the LPS-induced NO level was significantly higher than control (p < 0.01), and
that pretreatment with pioglitazone inhibits LPS-induced NO (p < 0.01). In contrast,
pretreatment with wortmannin enhanced the LPS-induced increase in NO generation (p <
0.05), and this pretreatment reversed the inhibitory effect of pioglitazone on LPS-induced
NO generation. The data were expressed as the percentage of control and were the mean
± SEM, from three independent experiments. (n=3) (**p < 0.01 versus. control, #p < 0.05
versus. LPS, ##p < 0.01 versus. LPS, &&p < 0.01 versus. Piog plus LPS).
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Figure 4. 11 Effect of PPARγ antagonist T0070907 on the LPS-induced NO production.
Primary microglia-enriched culture (2x105/well) was treated with T0070907 (1nM) either
alone or before pioglitazone treatment (10μM), followed by LPS administration (1μg/ml).
After 48hr, NO production was measured. Pretreatment with T0070907 significantly
reverses the inhibitive effect of pioglitazone on the LPS-induced NO production. The
data were expressed as the percentage of control and were the mean ± SEM, from three
independent experiments. (n=3) (***p<0.001 vs. control; ###p<0.001 vs. LPS;
&&&p<0.001 vs. corresponding pioglitazone plus LPS group).
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Discussion
In chapter 3, the results suggested that pioglitazone protects dopaminergic neurons by
inhibiting LPS-induced COX-2 expression and PGE2 synthesis via interference with NFkB and JNK pathways. In this chapter, the results demonstrate that 1) pioglitazone
protects dopaminergic neurons also via inhibiting LPS-induced iNOS and NO generation,
2) pioglitazone inhibits NO generation via inhibiting p38 MAPK activity, 3) the
inhibition of p38 MAPK pathway by pioglitazone might be via the activation of PPARγ
and PI3K pathway.
Pretreatment with microglia-enriched cultures with pioglitazone significantly
inhibited the LPS-induced increase in NO production. Previous studies have shown that
pretreatment with pioglitazone decreased iNOS-positive cells in the SN and striatum of
MPTP-treated mice (Dehmer et al., 2004) as well as decreased iNOS expression in the
intrastriatal LPS model (Hunter et al., 2007). These findings support our present results.
In addition, we failed to observe any inhibitory effect of pioglitazone on LPS-induced
NO production when pioglitazone was administered concurrent with LPS or 1hr after
LPS treatment, which suggests that PPARγ-mediated anti-inflammatory pathways and
LPS-mediated inflammatory pathways might target and interact with common active
molecules. There are several potential candidates that can be competitively targeted
within these two pathways. The first candidate is LPS-induced MAPK activation. As
Camp’s study demonstrated using 293T cells, PPARγ can be phosphorylated by p38
MAPK at its ser82 residue, and an increase in PPARγ phosphorylation may reduce its
sensitivity to PPARγ ligands such as pioglitazone (Camp and Tafuri, 1997; Camp et al.,
1999).

The second candidate is CD14, where LPS-induced microglia activation is

mediated by CD14. However, the PPARγ agonist 15d-PGJ2 and rosiglitazone negatively
regulate CD14 mRNA transcription in primary mouse microglia cultures (Xu and Drew,
2007); although, a caveat to this finding is that 15d-PGJ2 was recently shown not to be a
biologically relevant PPARγ agonist (Giri et al., 2004). A third candidate for competitive
targeting by LPS and PPARγ is RXR. Recent studies have shown that rosiglitazone
inhibits LPS-mediated RXR nuclear export, resulting in increased nuclear binding of
RXR in hepatocytes of mice (Park et al., 2004), and that the RXR agonist, 9-cis retinoic
acid, inhibits NO production by LPS-activated microglia (Xu et al., 2005). Our results
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also demonstrate that inhibition of iNOS, with its specific inhibitor 1400W, protects
dopaminergic neurons against LPS-induced neurotoxicity. This data is supported by a
previous study using an iNOS inhibitor to attenuate dopaminergic neuron loss after
intranigral LPS treatment (Arimoto and Bing, 2003).

Therefore, we speculate that

pioglitazone protects dopaminergic neurons at least via inhibition of iNOS expression
and function, which is consistent with other studies (Dehmer et al., 2004; Hunter et al.,
2007).
To further clarify which proinflammatory pathways might be involved in
mediating the inhibition of LPS-induced NO by pioglitazone, selective inhibitors for p38
MAPK (SB203580) and for JNK (SP600125) were administered before LPS stimulation.
It is interesting that inhibition of LPS-induced NO production was only observed with
administration of the p38 MAPK inhibitor, but not with the JNK inhibitor, in microgliaenriched cultures. These results suggest that p38 MAPK might be associated with LPSmediated iNOS regulation, but not with JNK.

In addition, our study showed that

pretreatment with pioglitazone before LPS reduces phosphorylation of p38 MAPK,
which suggests that pioglitazone inhibits LPS-induced iNOS and NO production via
suppression of p38 MAPK phosphorylation. Evidence has shown that inhibition of
different MAPK pathways is associated with decreases in LPS-induced NO production
(Bhat et al., 1998), where the inhibitory effect of p38 MAPK has been consistently
observed (Chen and Wang, 1999). In addition, our results are also consistent with two
recent in vivo studies which suggest a role for p38 MAPK, but not JNK, in LPS-induced
activation of iNOS (Ruano et al., 2006; Shibata et al., 2006).
Inhibition of PI3K with wortmannin did not enhance JNK phosphorylation upon
LPS stimulation. In contrast, wortmannin enhanced p38 MAPK phosphorylation upon
LPS stimulation in a dose-dependent manner, suggesting that PI3K/Akt mediated LPSinduced p38 MAPK activity and pioglitazone might inhibit LPS-induced NO generation
via regulation of PI3K/Akt activity.
Western blot analysis demonstrated that pioglitazone increases PPARγ activation
followed by PI3K/Akt activation, and LPS treatment has no significant influence on their
activation. On the other hand, PPARγ activation by western blot analysis was not found
in the primary neuron-enriched culture. The result suggested that the increased PI3K/Akt
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activity is mainly from microglia. Generally, these results suggest that activation of the
PI3K/Akt pathway by pioglitazone might be via PPARγ activation.

Whether the

activation of PI3K/Akt by pioglitazone is PPARγ dependent or independent needs to be
further clarified.
Our present study shows that inhibition of PI3K activity significantly enhances
LPS-induced NO production. Furthermore, pretreatment with wortmannin reverses the
inhibitory effect of pioglitazone on the LPS-induced increase in NO production,
suggesting that inhibition of NO by pioglitazone may be PI3K-dependent. Indeed, it
showed that inhibition of the P13K pathway enhances LPS-induced NO production in
macrophages (Park et al., 1997). A more recent study demonstrated that human iNOS
promoter induction by LPS/IFN-γ is suppressed by PI3K/Akt via inhibition of forkhead
transcription factor FKHRL1 (Kristof et al., 2006).
In the current study, it suggests that pioglitazone inhibits LPS-induced NO
synthesis via PPARγ-dependent mechanisms. The present results are supported by a
recent study on the mechanisms of iNOS inhibition by PPARγ agonist Rosiglitazone.
Their results demonstrated that ligand-binding causes SUMOylation on PPARγ, leading
to inhibiting the removal of corepressor complex by 19s proteasome on the iNOS
promoter, thus keeping iNOS transcription in an inactivated status (Pascual et al., 2005).
The current study shows that pioglitazone significantly inhibits LPS-induced
microglia-mediated iNOS expression and NO production. This might be mediated by
activation of the PI3K/Akt pathway, followed by inhibition of p38 MAPK activity, which
may contribute to the inhibitory effects of pioglitazone on LPS-induced NO generation;
thus, protecting dopaminergic neurons against LPS toxicity.

Copyright © Bin Xing 2008
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CHAPTER 5: Discussion and Conclusions
Summary of activated microglia-mediated neurodegeneration and its interference
with PPARγ activation
Microglia-dependent LPS neurotoxicity to dopaminergic neurons
The survival study of the dopaminergic neurons upon LPS insult in our culture system
showed that LPS-induced inflammation-mediated neurotoxicity is microglia-dependent.
The loss of dopaminergic neurons is only observed in the presence of microglia. Since
the finding that reactive microglia surround dopaminergic neurons in the SNpc of PD
patients (McGeer et al., 1988b), an increasing body of evidence suggested unlimited
microglial activation upon a variety of stresses may play a major role in the pathogenesis
of PD.

Although the role of activated microglia as an initial event leading to

dopaminergic neuronal death has still been under debate, however, the highest density of
microglia found in the SN of the brain provides the physical base of initial
neuroinflammatory response. The in vitro model has advantage over in vivo animal
model since the molecular mechanisms of activated microglia-mediated dopaminergic
neuronal death can be investigated more easily via dissecting “initial” pathological events
in microglia and “secondary” signaling transduction cascades occurring in the
dopaminergic neurons. On the other hand, it would be very helpful to identify microglia
subgroups with different phenotypic and physiological properties.

In this way, the

microglia subgroups which are more vulnerable to the stress signals and are mainly
responsible for the release of proinflammatory molecules can be selected out. It will
provide valuable tool to develop effective therapeutic strategy for Parkinson’s disease
and other neurodegenerative diseases.

The number of microglia decreased in the

pioglitazone plus LPS group. The cell counting in current study still can not tell whether
it is due to microglia apoptosis or necrosis. The TUNEL analysis could provide more
information.
PPARγ agonist pioglitazone protects dopaminergic neurons against activated microgliamediated NO and PGE2 via mediating MAPKs (p38 and JNK) and PI3K activity
PGE2 and NO released from activated microglia are shown to be neurotoxic to
dopaminergic neurons in primary neuron-microglia cultures. Pharmacological inhibition
of JNK and p38 pathways suggests that PGE2 and NO generation induced by LPS might
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be differentially mediated by JNK and p38 pathways respectively, consistent with other
studies (Pyo et al., 1998; Han et al., 2002). The different report from another study
(Wang et al., 2004) might be due to different cell types in which BV-2 microglia was
used. Interestingly, no change of p38 MAPK phosphorylation was observed with the
inhibition of PI3K by wortmannin in the absence of LPS stimuli. In contrast, western
blot analysis showed that inhibition of PI3K activity before LPS insult significantly
increases the phosphorylation of p38 other than JNK, suggesting PI3K negatively
mediate LPS-induced p38 activity. The results from the NO assay also support this
finding, showing PI3K inhibition in the primary microglia-enriched culture reverses the
inhibitive effect of pioglitazone on the LPS-induced NO generation, strongly suggesting
PPARγ agonist pioglitazone suppresses induced-NO in a PI3K-dependent manner. This
first report is further supported by the observation in western blotting analysis, showing
that pioglitazone increases the phosphorylation of PPARγ, followed by PI3K / Akt
activation in both pioglitazone treated group and LPS treated group.

Due to that

pioglitazone is administered before LPS treatment, and pioglitazone alone increase
PI3K/Akt activity, its increases seen in LPS group are more likely originated from
pioglitazone-induced PPARγ activation. Since no change of PPARγ activation was found
in primary neuron-enriched culture upon pioglitazone and LPS treatment, it is more likely
that the neuroprotective effect of pioglitazone is originated from its dynamic influence on
the microglia but not on the dopaminergic neurons, which is supported by the evidence
that PPARγ has only low expression in normal neurons and in the SN even upon MPTP
insult (Dehmer et al., 2004; Cimini et al., 2005). Interestingly, a pharmacological PPARγ
inhibition study using T0070907 suggested that pioglitazone inhibits LPS-induced NO
production in a PPARγ-dependent, however, inhibition of LPS-induced PGE2． synthesis
by pioglitazone appears PPARγ-independent. It is interesting to know whether LPSinduced PGE2 and NO can in turn influence the phosphorylation of PPARγ in a
differential way.
In summary, pioglitazone protects dopaminergic neurons by inhibiting iNOS and
COX-2 expression via interference with p38 MAPK and JNK / NF-kB in a differential
mediating manner, either in a PPARγ-dependent or PPARγ-independent way.
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Furthermore, the inhibition of iNOS / NO may be mediated by the activation of PPARγ
and PI3K / Akt pathway.
Potential areas for the further inquiry
To investigate more effectively whether PPARγ agonist inhibition of LPS-induced NO
and PGE2 synthesis follows PPARγ-dependent mechanisms, knockdown of PPARγ in the
primary microglia-enriched cultures could answer this question directly.

The other

question which is interesting to know is the potential feedback influence of PGE2 and NO
on the PPARγ activity either in microglia-enriched culture or in primary neuron-enriched
cultures. Another question that was not directly addressed is the detailed signal
transduction pathways related to LPS-induced inflammation and oxidative stress in the
dopaminergic neurons, this could be explored via using conditioned medium from
activated microglia culture.
Extrapolation to Parkinson’s disease
From the extracellular signals to intracellular signaling transduction for either cellular
survival or death, numerous activated molecules take part in this very complicated
process. MAPKs and PI3K are the candidates to be preferred targeted and modified since
1) their signaling cascades are well understood; 2) they are associated with the death or
survival signaling. PPARγ agonists have a broad spectrum of biological functions, from
lipid metabolism in the peripheral tissue to the anti-inflammatory and antioxidant
properties in the central nervous system, providing a very wide range that can be utilized
to design effective and selective therapeutic strategies. By dissecting the molecular role
of PPARγ activation in the neuroinflammation-mediated MAPKs and PI3K pathways, the
downstream executive molecules can be identified. In this way, the undesirable and side
effects of PPARγ activation on the survival of dopaminergic neurons can be removed by
specific pharmacological inhibition or gene modification. For example, what is the
consequence of long-term treatment of PPARγ agonists in Parkinson’s disease? What is
the long-term effect of PPARγ agonists on the astrocytes and microglia? The concern is
not unnecessary since one study on the human astrocytic cells implicated its apoptotic
property on these cells (Chattopadhyay et al., 2000). The current study suggested that
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MAPKs pathways have differential function on the mediation of LPS-induced NO and
PGE2 level, and PPARγ activation inhibits their synthesis probably via PI3K activation
and accordingly potential differential regulation of MAPKs activity. The further study on
the physiological function of PPARγ and their roles in the proinflammatory process may
be very useful to investigate the possibility of clinical therapy, and further understanding
the molecular mechanisms of PPARγ agonists on their anti-inflammatory features in
terms of receptor-dependent or receptor-independent will be very helpful to develop
PPARγ synthetic drugs with efficacy and safety.
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